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Abstract
The existing protocol for the screening of natural products from marine invertebrates and
macroalgae has been demonstrated successfully at VUW on multiple occasions. This
study describes the evaluation of an adapted version of the protocol to screen liquid
microbial cultures. The adapted protocol was carried out using an NMR-guided approach
and was used to screen 10 New Zealand extremophilic microbes. Investigation of the
bacteria Anoxybacillus flavithermus led to the isolation of the known compound 1-acetyl-
β-carboline (25), which was briefly evaluated for its biological activity. A detailed
investigation on the marine bacteria Shewanella sp. resulted in the isolation of indole-
3-carboxaldehyde (93) and 14 known 2,5-diketopiperazines (36, 38, 41–44, 53, 54, 94–
99). Three of the isolated 2,5-DKPs were tested against Saccharomyces cerevisiae to
evaluate their antifungal activity, the results of which are also described. Overall, the use
of the adapted screening method proved successful to guide the isolation of secondary
metabolites from microbial cultures.
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The existing protocol for the screening of natural products from marine invertebrates
and algae has been demonstrated successfully at VUW on multiple occassions. This
study describes the evaluation of an adapted version of the protocol to screen water-
based microbial cultures. The adapted protocol was carried out using an NMR-guided
approach and was used to screen ten New Zealand extremophilic microbes. Investigation
of the bacteria Anoxybacillus flavithermus led to the isolation of the known compound
1-acetyl-β-carboline, which was briefly evaluated for its biological activity. A detailed
investigation on the marine bacteria Shewanella sp. resulted in the isolation of indole-
3-carboxaldehyde. Three of the isolated 2,5-DKPs were tested against Saccharomyces
cerevisiae to evaluate their antifungal activity, the results of which are also described.
Overall, the use of the adapted screening method proved successful for the isolation of
natural products from microbial cultures.
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Chapter 1
Introduction
1.1 The Role of Natural Products in Drug Discovery
Natural resources have been used as herbal remedies for pain and disease for thousands
of years. The active constituents of these remedies were unknown at the time and
led scientists to explore the medical use of plants in more detail.1 In 1785, Withering
described the use of a cardiotonic foxglove extract to treat heart patients, which later led to
the discovery of digoxin (1), a drug for treating cardiac arrhythmias and congestive heart
failure.2 Shortly after, in 1804, Sertu¨rner isolated morphine (2) from opium and found
it to be an analgesic and a sedative, which made it the first naturally derived substance
to be commercialised.1 Following the discovery of 2, several other natural products were
identified including salicin (3) from Salix alba, quinine (4) from Cinchona ledgeriana,
nicotine (5) from Nicotiana tabacum and many more.1 These compounds have displayed
significant biological activities in humans, with many still in use. This highlights the
important role that natural products play as drugs or potential drug leads. Fleming’s
discovery of penicillin (6) in 1928 illustrated that plants were not the only source of
bioactive natural products.3 His discovery brought about the onset of the “Golden Age of
Antibiotics” during which microbes were largely screened for new bioactive compounds.4
The ability of natural products to exert a biological effect on humans and other
organisms has long been questioned. Organisms that exist in close proximity to one
another can produce small, diverse molecules known as secondary metabolites. The
production of these compounds is metabolically expensive and hence they must have some
advantage to the producer such as aiding in defending themselves from their neighbours,
communicating with their population or even interfering with competing neighbours.5
Natural selection over time causes these secondary metabolites to evolve and become
more bioactive and bioavailable.1 The small molecular size of these metabolites and their
inherent bioactivity allows them to bind to receptors and exert various effects in humans.5
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The increase in knowledge and tools for analytical and structural chemistry in the 20th
century has led to the discovery of a large number of bioactive natural products from
plants and microbes. These compounds have contributed largely to the field of drug
design by providing novel chemical scaffold targets that can be synthesised and modified
in order to enhance bioactivity.1 Although natural products are a strong source of drug
leads, over the last decades, many pharmaceutical companies decided to switch their
attention to combinatorial chemistry and high-throughput screening for identifying new
drug candidates. This was due to long purification time frames and lack of access to
new sources of natural products.6 However, in a recent review of new drugs approved
by the FDA from 1981–2010, it was reported that over 50% of all new approved drugs
were either natural products or derived from natural products.7 Also highlighted was the
important role that these compounds play as anticancer, anti-infective and antidiabetic
agents. Therefore, despite the few disadvantages mentioned above, it is due to the
almost everlasting supply of unique chemical scaffolds provided by natural products that
scientists have switched their attention back to natural product research in the past few
years.8
2
1.2 Microbes as Sources of Natural Products
1.2.1 Terrestrial and Freshwater Microbes
The discovery of penicillin (6) led to the extensive screening of microbes, particularly
soil actinomycetes and fungi, for more antibiotics. The genus Streptomyces has not
only provided almost 75% of currently commercialised antibiotics, it has also provided
compounds with anticancer activity.9 Bleomycin (7), a non-ribosomal glycopeptide
isolated from Streptomyces verticillus, obtained FDA approval in 1973 as an anticancer
agent.10 Daunorubicin (8), an antibiotic isolated from Streptomyces peucetius and
doxorubicin (9), the semi-synthetic version, are both DNA intercalating drugs that were
commonly used against a wide range of cancers before issues of cardiotoxicity arose
in 1967.11 Despite this, 9 is still used as an orphan drug for the treatment of acute
lymphocytic leukaemia.5 Several other anticancer agents isolated from actinomycetes are
currently undergoing different phases of clinical trials.
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Cyanobacteria are another leading source of bioactive secondary metabolites. The
prokaryotic cellular organisation of these microbes resembles bacteria but they can
perform photosynthesis similar to algae.12 Cyanobacteria are known to produce both
harmful and beneficial molecules. In 1878, George Francis observed an algal bloom
of Nodularia spumigena in an estuary of the Murray River in Australia. It was reported
that wildlife that consumed this water died a terrible and rapid death. This was the first
reported incidence of cyanotoxins.13 Since then, several cyanotoxins have been isolated
from various species including microcystin (10) and nodularin (11) which are hepatotoxic,
and neurotoxins such as anatoxin (12) and saxitoxin (13).14 Despite their production of
toxins, these bacteria are still considered important sources of novel drug leads that exhibit
various activities including antibiotic, antiviral, antifungal, cytotoxic, immunosuppressive
and more.13 Antiviral compounds that have been isolated include chlorinatedβ-carbolines
(14) from the terrestrial cyanobacterium Dichotrix baueriana, which act against Herpes
simplex virus 2,15 and the protein cyanovirin-N from Nostoc ellipsosporum that inhibits
cell to cell transmission of HIV.16 Cryptophycin (15) is a cytotoxic agent that is currently
undergoing clinical trials.14 It was originally isolated from a Nostoc sp. as an antifungal
agent but development was abandoned due to toxicity.17 It was later isolated again from
another Nostoc sp. and demonstrated powerful cytotoxicity against tumor cell lines, up
to 1000 fold greater than the chemotherapeutic agent paclitaxel, making it a promising
anticancer agent.14
Myxobacteria are another group of microbes that have been screened for their production
of bioactive compounds. They have an unusual life cycle that includes the ability to glide
and to form multicellular fruiting bodies.18 Ambruticin (16), an orally active antifungal
agent, was the first metabolite reported from the myxobacterium Sorangium cellulosum
in 1977.19 The genus Sorangium is responsible for producing almost 50% of the bioactive
natural products that have been isolated from this group of bacteria.20 Epothilones isolated
from the genus Sorangium are a well known class of structurally unique anticancer agents.
All six isolated so far act in a similar way to paclitaxel, by stabilising mictrotubules and
interfering with cell division.21 Epothilone B (17) and its analogues are currently under
various phases of clinical trials.21
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1.2.2 Marine Microbes
Marine organisms have been investigated over several decades for their production of
natural products, with the focus being on marine invertebrates.22 Only a small percent
of the overwhelming numbers of marine microbes have been researched in the past as
these microbes were “uncultivable” in the laboratory.23 However, recent developments
in culture technologies have overcome this limitation and made previously unculturable
microbes accessible in culture.23 Hence, these microbes have recently been given the
spotlight for natural product investigation. The high salt and potentially high pressure
environment that these microbes live in allow them to produce interesting metabolites
that help them survive and compete in these conditions.24
A large number of bioactive metabolites have been isolated from marine microbes and
are currently undergoing preclinical studies or clinical trials. Two examples are the
compounds thiocoraline (18) and salinosporamide A (19), isolated from marine actino-
mycetes Micromonospora marina and Salinospora tropica, respectively.25,26 Compound
18 is a potent DNA polymerase inhibitor and shows strong activity against several
tumor cell lines. It also exhibits strong antimicrobial activity against Gram-positive
microorganisms and is currently undergoing preclinical trials.27,28 Compound 19 is a
potent proteasome inhibitor and has high cytotoxic activity against cancer cell lines.26
It is currently undergoing Phase I human clinical trials for multiple myeloma.29
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Marine invertebrates such as sponges can host various symbiotic microbes. It has been
reported that several bioactive compounds previously thought to be produced by sponges
were actually produced by their symbionts.30 Examples include diketopiperazines pro-
6
duced by Micrococcus sp. previously ascribed to the host sponge Tedania ignis,31 and
brominated biphenyl ethers produced by the bacterium Vibrio sp. formerly attributed to
the host sponge Dysidea sp..32 Since only about 0.01% of the marine biodiversity has
been explored, this remains an active area of research for novel drug leads.22
1.2.3 Extremophilic Microbes
In 1969, Brock and Freeze discovered the thermophilic bacterium Thermus aquaticus in
the hot springs of Yellowstone National Park.33 Although thermophiles that could thrive at
temperatures up to 60 ◦C were known before this time, the ability of T. aquaticus to grow
at temperatures greater than 70 ◦C caused it to be named the first extreme thermophile.33
Shortly after, the hyperthermophile Sulfolobus acidocaldarius was discovered by the same
group from extremely hot and acidic springs in the same area. It was found that it could
survive at a pH range of 2–3 and temperatures up to 85 ◦C making it acidophilic as well as
thermophilic.34 Following the discovery of these microbes, the term “extremophile” was
coined by MacElroy to describe organisms that can thrive in extreme environments.35 It is
important to note that “extreme environment” is a relative term, since environments that
are extreme for one organism may be essential for the survival of another organism. Thus,
extremophiles can be defined as organisms that can grow and reproduce under conditions
that would kill most other creatures, and include some that cannot survive in the normal
anthropogenic global environments. To date, several classes of extremophiles have been
discovered including thermophiles (50 to >80 ◦C), psychrophiles (<10 ◦C), alkaliphiles
(pH >10), acidophiles (pH <4) and halophiles (>2.5 M NaCl).36
Although extremophiles were discovered over 30 years ago, they have been given
the spotlight for research over the past two decades as scientists realised that the
molecules that allow these microbes to survive in extreme conditions could potentially
be useful for several applications. This led to extremophiles being investigated for their
enzymes, which are termed “extremozymes”, as they are active and stable under extreme
conditions.37 Thermostable DNA polymerases from extremophiles have successfully
demonstrated their use in the polymerase chain reaction (PCR), with the most widely
7
used extremozyme being Taq polymerase, named for its isolation from T. aquaticus.38
Extremozymes have also been used in the food, pharmaceutical, paper and textile
industries and have potential applications for bioremediation.38
Over the past few years, Don and Andrea Stierle have reported the isolation of several
bioactive metabolites from extremophiles present in the Berkeley Pit Lake. In 2003, they
isolated four new tyrosine derivatives from an extremophilic fungus, Pithomyces ellis.39
They found that a prenylated phenol (20) was a 5-HT receptor ligand, suggesting that it
could have antihypertensive properties. Soon after, in 2004, they isolated two novel hybrid
polyketide-terpenoid metabolites from Penicillium rubrum from the same lake.40 Both
berkeleydione (21) and berkeleytrione (22), inhibited matrix metalloproteinase-3 and
caspase-1, indicating that they could be potential anti-inflammatory or anticancer agents.
In 2006, the novel spiroketal berkelic acid (23) was isolated from another Penicillium
sp., and showed anti-inflammatory activity and selective inhibition of ovarian cancer cell
lines.41 The Stierles have gone on to isolate many more bioactive metabolites from P.
rubrum.42,43 These findings demonstrate that a single extreme environment can be home to
various extremophilic microorganisms that produce several unique metabolites covering
a range of activities. To date, hundreds of unique bioactive secondary metabolites have
been isolated from all the major classes of extremophiles,35 making these microbes a very
attractive source for novel drugs leads.
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1.3 Isolation Guidance for Natural Products
The aim of natural products research is to provide chemists with novel unique chemical
structures that possess potentially useful biological activity. In order to prioritise which
cultures or organisms contain interesting secondary metabolites, an initial screen is carried
out on the cultures or extracts to scan for the presence of such compounds. Semi-
purified fractions from the screen or a bulk-scale processing of the chosen organism(s)
are then further fractionated using various types of chromatography to isolate the desired
metabolite(s) until they are pure enough for structure elucidation and biological profiling.
The purification process is aided by a technique that can identify the presence of the
desired metabolite at each step of fractionation. The technique used to initially screen
for interesting metabolites is usually also used to guide the isolation process. Bioassay-
guided and Nuclear Magnetic Resonance (NMR) spectroscopy-guided isolation are two
contrasting techniques that are currently used to aid natural product isolation at VUW.
The advantages and disadvantages of both techniques are discussed below.
1.3.1 Bioassay-Guided Isolation
Bioassay-guided isolation is the most commonly used guidance technique for isolating
novel and bioactive secondary metabolites from microorganisms.44 The main goal of
this technique is to screen for the presence of bioactive compounds. After each step
of fractionation, a bioassay is carried out on every fraction and only those possessing
bioactivity are further purified and screened using the same bioassay, thus allowing
purification of the compound responsible for the bioactivity. The obvious advantage
of using this technique is that a compound that possesses some type of bioactivity is
almost always isolated. The type of bioactivity exhibited by the compound depends on
the type of bioassay(s) used to track the isolation process.45 An ideal bioassay would be
highly sensitive to small amounts of active material, selective to the specific bioactivity,
cost effective and easy to run and maintain.46 In general, there are two broad classes
of bioassays that can be used for screening: cell-based (cytotoxicity) and enzyme-based
bioassays.46
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Cell-based assays test the interactions of the compounds within a fraction with whole
intact cells. These assays measure cytotoxicity, or the ability of the compounds present
to simply kill or inhibit the proliferation of cells in culture.45 An advantage of cell-based
assays is that they eliminate fractions containing compounds that are unable to enter or
that are rapidly metabolised by the cell, characteristics which are unwanted in a drug.47
Though it is usually not possible to determine the exact mode of action of the compounds
with these assays, a wide range of active compounds can be detected, giving these assays
a higher hit rate than enzyme-based assays.46 The ability to screen for a wide variety of
active compounds can also serve as a disadvantage in that it makes these assays much less
specific and compounds present in low concentrations may not be detected even if they
are bioactive, due to the presence of other bioactive compounds in higher concentrations.
Another disadvantage of these assays is that they are much more time consuming than
enzyme-based assays and often take a few days instead of a few hours. However, the use
of whole cells in these assays makes them much more comparable to in vivo processes
and serves as the major advantage in using them for bioactive natural product screening.44
Enzyme-based assays measure interactions of the compounds in a fraction with a single
drug target, usually a specific enzyme or receptor protein. These assays are highly
sensitive and only take a few hours to carry out, making them amenable to high-
throughput screening and automation.48 Although there is an advantage of obtaining a
compound with a known target and potential mechanism of specific activity,46 this method
has several disadvantages. Compounds that are not active in the enzyme-based assay
may be active in vivo if the compound acts by a different mechanism or if the inactive
compound is metabolised in vivo to an active analogue. Conversely, compounds that are
active in the assay may not be active in vivo if the compound does not penetrate the cell
membrane.47 Despite these disadvantages, enzyme-based assays are still widely used due
to their higher specificity and efficiency over cell-based assays.
As mentioned above, bioassay-guided isolation almost always leads to the isolation of a
bioactive compound. However, this technique suffers from several drawbacks. The cost
of running bioassays on each fraction after each step can be quite high depending on the
type of bioassay. There is no way to eliminate the isolation of known compounds with
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this technique since structure elucidation is only carried out after the active compound
is isolated. Additionally, novel compounds that do not exhibit bioactivity in the selected
assays will not be isolated. The major disadvantage however, is that valuable amounts
of the active compound are being wasted after each step of fractionation since samples
cannot be recovered after a bioassay, and this could lead to an insufficient amount of the
pure compound for structural identification at the end, be it novel or known.
1.3.2 NMR Spectroscopy-Guided Isolation
NMR-guided isolation is a useful technique for isolating novel chemotypes. The premise
of this method is that novel chemotypes should possess novel biological activity as
secondary metabolites are biochemically expensive to produce and therefore production
of inactive natural products should have been lost via natural selection.1 After each
step of fractionation, 1D (1H NMR) or 2D (COSY, HSQC, HMBC) NMR spectra are
obtained for each fraction. The isolation process is tracked by comparing NMR signals
from parent fractions with their daughter fractions, with further fractionation of only
those daughter fractions that contain the NMR signals of the interesting compounds
highlighted in the original fraction. Using 1D and 2D NMR spectra, substructures of
compounds present in a single fraction can be identified and these can be submitted to
database searches (MarinLit,49 AntiBase,50 Scifinder Scholar,51 etc.) resulting in a list
of known compounds. If a compound in the fraction shows similar NMR signals to a
compound in the list, the purification process of this compound can be discontinued. This
allows for the identification of known compounds as early as possible during the isolation
process to avoid unnecessary work on uninteresting compounds, a process known as
dereplication, and thus is a major advantage of the NMR-guided method over bioassay-
guided isolation.52
The NMR-guided isolation technique also allows for the targetting of more than one novel
compound from a single fraction. Moreover, there is no loss of valuable amounts of
the novel compound as samples can be recovered after obtaining NMR spectra.53 After
purification and structure identification of the novel compounds, bioassays such as those
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discussed above can be run to establish their activity, if any. This method provides
an efficient way of isolating several, if not all, novel potentially bioactive secondary
metabolites from a bacterial culture. The disadvantages of this method are that it is
slower and less amenable to automation. It is also possible that any isolated novel
compounds may not possess bioactivity in the chosen bioassays. However, this should not
be seen as a major disadvantage as it still leads to the discovery of novel unique chemical
structures that potentially exhibit a novel biological activity, which can be tested by using
modern genome wide screens such as yeast chemical genetics that are good for broad
bioactivity determination.54 Due to the advantages of this method over bioassay-guided
isolation and for the purpose of isolating novel secondary metabolites from microbes,
NMR spectroscopy-guided isolation is used during this project.
1.4 Techniques for Isolation of Secondary Metabolites
A bioactive secondary metabolite must usually possess both hydrophobic and hydrophilic
(i.e. they must be amphiphilic) characteristics that enable the molecule to easily transverse
through cell membranes and other biological barriers.55 Cultures and crude extracts of
organisms will initially contain a wide range of compounds with varying degrees of
polarity, ranging from polar amino acids, salts and sugars to non-polar fats, lipids and
steroids.52 Due to their amphiphilic nature, most secondary metabolites will elute between
the polar and non-polar extremes from a chromatographic stationary phase. This is best
explained in terms of a mass window (Figure 1.1), where the intermediate region of the
window usually contains most of the secondary metabolites but only a small amount of
mass due to the absence of primary metabolites. This feature makes the mass window an
ideal target during the first stage of fractionation of a culture or extract.
1.4.1 Cyclic Loading and Back Loading
Cyclic loading is a technique developed by Northcote and West to fractionate crude ex-
tracts of marine invertebrates by separating the undesirable highly polar salts and primary
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Figure 1.1. Typical mass distribution in a microbial culture or extract eluted from a
reversed-phase stationary phase.
metabolites (both polar and non-polar) from amphiphilic compounds of interest.52,56 The
technique utilises reversed-phase poly(styrenedivinylbenzene) (PSDVB) as the stationary
phase. PSDVB is an inexpensive, chemically inert, crosslinked polymeric resin that is
highly porous, lacks polar sites, and is stable over a large pH range. It is also fully
reusable and provides reproducible chromatography.52
The first stage of cyclic loading involves passing the extract through the PSDVB column.
This allows most of the non-polar compounds in the extract to adhere to the PSDVB
beads. The eluent is then diluted to 50% (v/v) of its concentration by the addition of
water. Addition of water to a crude extract would usually result in the precipitation of
non-polar compounds but this does not happen with cyclic loading, as most of the non-
polar fats and triglycerides would have adsorbed to the column during the first pass and
will no longer be present in the diluted extract. The diluted extract is then passed through
the same column again, with the mid polar compounds adsorbing to the PSDVB (Figure
1.2). As the eluent is gradually made more polar by each dilution with water, more polar
compounds in the extract are adsorbed to the column. The cyclic process is repeated
until all the compounds of interest are adhered to the PSDVB, usually when the extract
is 25% or 12.5% (v/v) of its original solvent concentration. The column is then washed
with water to remove any salts, and then eluted using a stepwise or a gradient system
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Figure 1.2. Cyclic loading.
of increasing organic modifier (Me2CO or MeOH) in water, which results in fractions of
decreasing polarity. Thus, the earlier fractions will contain polar metabolites and the later
fractions will contain non polar metabolites, with the mid polar secondary metabolites
contained in the fractions collected in between.
Reversed-phase chromatography often generates many samples with high water content,
which are time-consuming and sometimes difficult to evaporate under reduced pressure
as they often “bump”. This problem can be overcome by using an extension of the cyclic
loading method, back loading. The technique involves cyclic loading the fraction that
contains water onto a smaller PSDVB column as described above. A smaller column
can be used as the mass contained within the fraction of interest will only be a small
proportion of that contained in the original parent fraction. The column is then eluted
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with a small amount of pure organic solvent, generating a fraction which is much easier
to evaporate with less bumping. Back loading can also be used to adsorb compounds in a
fraction to a small amount of stationary phase, which can then be transferred as a slurry
to a larger column for better chromatographic separation of the fraction.52
1.4.2 VUW Screening Method
Our approach to screening organisms and isolating interesting novel compounds is to
analyse their extracts by 1D and 2D NMR spectroscopy. The cyclic loading method is
used to pass the extracts through a PSDVB column. For the initial crude separation,
the column is eluted with 30% Me2CO/H2O, 75% Me2CO/H2O and 100% Me2CO to
give three fractions. As discussed above, the 30% fraction should contain the most
polar compounds and the 100% fraction should contain the most non-polar compounds.
The secondary metabolites of interest should, therefore, elute in the mid-polar 75%
fraction. The back loading technique is used to reduce water content in the 30% and 75%
Me2CO/H2O fractions. Fractions obtained from the screens are then further fractionated,
with emphasis on the mid-polar fractions. Fractionation is carried out using different
types of chromatography including normal and reversed-phase, size exclusion and HPLC
for final steps of purification. NMR spectra are obtained for all fractions following each
stage of purification.
1.5 Research Aims
Bioactive natural products have been isolated from a multitude of microbial species. As
terrestrial and freshwater microbes were easily available and culturable, initial natural
product research was focussed on these microbes which led to the isolation of many novel
drugs and drug leads. However, due to the realisation that there are large numbers of
unexplored microbial species in the marine and extreme environments, these microbes
have recently been given the spotlight for natural product research. Moreover, their
ability to survive in their unique environments allows them to produce unique metabolites
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that serve as novel scaffolds for drugs and drug leads. Many bioactive metabolites have
already been isolated from these microbes, and many more are left to be discovered. It
is due to this reason that this research was aimed at validating and extending the use of
the VUW NMR-guided screening method for the isolation of secondary metabolites from
New Zealand extremophilic microbes.
Isolation of the secondary metabolites was carried out using an adapted version of the
VUW screening method (described in Chapter 2) and was guided by NMR spectroscopy.
Once a compound was purified, structure elucidation was carried out using mass
spectrometry (MS) and both 1D and 2D NMR spectroscopy. After structure elucidation,
interesting compounds were tested for their bioactivity using one or both classes of
bioassays discussed in Section 1.3.1.
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Chapter 2
Extremophilic Microbes Investigated by Spectroscopic
Screening
The microbes investigated in this research were chosen according to their availability
as cultures from GNS Science and Callaghan Innovation. During the course of this
research, a total of 10 microbial strains (nine bacteria and one fungus) were screened
to establish their secondary metabolic profiles. The details of nine microbial strains that
were isolated from areas in the Taupo Volcanic Zone (TVZ) and the results of their screens
are described in this chapter. A detailed investigation of a marine Shewanella sp. was
also carried out during this research and led to the isolation and identification of several
2,5-diketopiperazines. These results are discussed in detail in Chapter 3. The culture
conditions for all the investigated microbes are presented in Appendix A.
For strains NGM11.1, NGM22.9, WAP10.3.2, WC14 and WK1, the isolated strain met
the phylogenetic requirements to be considered the same as species described (based on
16S rRNA gene sequence similarity), and therefore for the purposes of the following
sections were treated as having the same general genetic and phenotypic characteristics.
However, it should be noted that some phenotypic and genotypic characteristics may vary
from the described strain due to horizontal gene transfer and other evolutionary factors.
2.1 Taupo Volcanic Zone
The TVZ stretches from Mount Ruapehu in Tongariro National Park, through Rotorua,
to White Island in the Bay of Plenty (Figure 2.1), and is responsible for most of New
Zealand’s current volcanic activity. The zone is approximately 300 km long and up to
60 km wide and consists of numerous volcanic vents and geothermal fields. It includes
three frequently active cone volcanoes (Mount Ruapehu, Mount Ngauruhoe and White
Island), and two of the most productive calderas (large, deep craters caused by volcanic
17
Figure 2.1. Taupo Volcanic Zone (highlighted in red) in the North Island, New Zealand.
Sourced from Land Information New Zealand.
eruptions) in the world (Okataina and Taupo). The geothermal fields within this region
exhibit a wide range of geothermal features including hot and boiling springs and streams,
geysers, silica sinter deposits, mudpools, fumaroles, hot and steaming ground, altered
ground and hydrothermal eruption craters, and many more. The hot water from these
areas may form underground reservoirs that can be drilled to provide hot water and steam
for electricity generation (e.g. Wairakei Power Station, which has now been operating for
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almost 50 years) or other industrial and heating applications. However, these features are
very susceptible to damage from activities associated with all forms of land modification,
but particularly farming, forestry and mining (e.g. for sulphur). These geothermal regions
contain organisms that have evolved to withstand high temperatures and/or highly acidic
conditions, and are potentially unique to these areas. As there have been no reports of
secondary metabolites from microbes that reside in the geothermal fields of the TVZ,
they remain an attractive target for natural product research. Moreover, it is important
to explore these microbes in terms of their metabolic profiles before their habitats are
compromised due to land modification.
2.2 Adapted Screening Method
The VUW screening method described in Section 1.4.2 has been used successfully in
the VUW Natural Products laboratory for screening extracts of marine invertebrates
and macroalgae. However, this method has not been tested on microbial cultures and,
therefore, had to be adapted for the screening of microbes. The microbial cultures
containing the metabolites were water-based and also contained some cell mass. To
separate the cell mass from the supernatant, each microbial culture was filtered using
filter paper and celite. The supernatant was passed through a PSDVB column. The cyclic
loading method was not used for loading the supernatant as it was essentially water-based
and thus could not be made more polar. Instead, the supernatant was passed through
the column more than once to ensure that all or most of the compounds had adsorbed
onto the PSDVB resin by increasing the residence time of the supernatant. The filtered
cell mass was extracted in MeOH and the cyclic loading method was used to pass the
cell mass extract through another PSDVB column. The columns were then batch eluted
separately with 30% Me2CO/H2O, 75% Me2CO/H2O and 100% Me2CO and the fractions
were analysed by NMR. This initial crude separation step was carried out for both the
supernatant and cell mass from all the cultures.
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2.3 Investigation of Thermus filiformis (NGM11.1)
Thermus filiformis is a Gram-negative, thermophilic, filamentous bacterium that was
first isolated in 1987 by Hudson et al. from a New Zealand hot spring.57 Following
its isolation, research on this bacterium was focussed on the characterisation of its
enzymes such as nucleases, DNA polymerases, ligases and α-amylases for applications
in DNA replication.58–60 NMG11.1 was isolated from Radiata Pool (Figure 2.2) at the
Ngatamariki Power Station located 17 km northeast of Taupo. At the time of isolation,
the pool water was at a temperature of 68 ◦C and a pH of 7.2. Phylogenetic studies of this
isolate carried out at GNS Science identified it as T. filiformis.
Figure 2.2. Isolation site of NGM11.1 and NGM22.9.
Image courtesy of Matthew Stott, GNS Science.
A 3 L culture of NGM11.1 and cell mass extract were screened as described above. The
1H NMR spectra of the 75% Me2CO fractions from the culture filtrate (CDB02 09E) and
cell mass extract (CDB02 11E) showed many major resonances pertaining to the culture
medium, which masked possible metabolite signals. However, a few unique peaks were
observed (highlighted in Figure 2.3), but these were not pursued further due to lack of
available biomass.
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Figure 2.3. Spectral comparison of the 75% Me2CO fractions from the NGM11.1
culture filtrate (top) and cell mass extract (bottom) with unique resonances highlighted
(600 MHz, CD3OD).
2.4 Investigation of Geobacillus stearothermophilus
(NGM22.9)
Geobacillus stearothermophilus is a Gram-positive, thermophilic, rod-shaped bacterium.
Since its first isolation in 1920,61 it has been extensively researched for its thermostable
enzymes. However, over the past few years, research on G. stearothermophilus has
focussed on its role in the spoilage of food. The spores of this bacterium are highly
heat-resistant and this property makes it useful as a biological indicator for evaluation of
sterilisation processes.62 NMG22.9 was isolated at the same site as NGM11.1 (Figure
2.2). Phylogenetic studies of this isolate carried out at GNS Science identified it as G.
stearothermophilus.
A 1 L culture of NGM22.9 and cell mass extract were screened as described above.
The 1H NMR spectrum of the 75% Me2CO fraction from the culture filtrate showed no
significant peaks other than those belonging to the culture medium. As a result, no further
investigation was done on this microbe.
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2.5 Investigation of Anoxybacillus amylolyticus
(WAP10.3.2)
Anoxybacillus amylolyticus is a Gram-positive, rod-shaped, thermophilic bacterium that
was first isolated in 2006 by Poli et al. from geothermal soil at Mount Rittmann in
Antartica.63 Its very recent identification makes it a relatively unexplored microbe. In
the past few years, research on this bacterium has been focussed on the effects of heavy
metals on its α-amylase production.64 WAP10.3.2 was isolated from lake-side sediments
and gravel found at the Waipahihi foreshore in Taupo. The sediments at the isolation site
were at a temperature of 66.9 ◦C and a pH of 6.5. Phylogenetic studies of this isolate
carried out at GNS Science identified it as A. amylolyticus.
A 1 L culture of WAP10.3.2 and cell mass extract were screened as described above.
Some unique proton resonances were seen in the 1H NMR spectrum of the 75% Me2CO
fraction (CDB01 92E) from the cell mass extract (highlighted in Figure 2.4). However,
due to lack of biomass, this microbe was not investigated further.
_DH_D9D_9DE9De9DH9DED_EDEEDeEDHEDMD_MDEMDeMDHMDeD_eDEeDeeDHeDOD_ODEODeODH

96 (
666_9E9H__
Figure 2.4. 1H NMR spectrum of the 75% Me2CO fraction from the WAP10.3.2 cell
mass extract with unique resonances highlighted (600 MHz, CD3OD).
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2.6 Investigation of Thermomyces lanuginosus (WC14)
Thermomyces lanuginosus, previously named Humicola lanuginosa, is a thermophilic
fungus that was first isolated by Tsiklinskaya in 1899 from a potato that had been
inoculated with garden soil and then kept at 52–53 ◦C.65 This fungus has been studied
over several decades for its production of thermostable enzymes. To date, a very large
number of thermostable T. lanuginosus enzymes have been purified and characterised
including lipases, amylases, xylanases, galactosidases, invertases, mannases, pectinases
and many more.65–68 Many of these enzymes play an important role in the biochemical,
food and paper industries.65 WC14 was isolated from a heated wood-chip pile in Taupo.
Phylogenetic studies carried out at GNS Science identified it as T. lanuginosus.
A 2 L culture of WC14 and cell mass extract were screened as described above. The
1H NMR spectrum of the 75% Me2CO fraction from the culture filtrate showed no
significant peaks other than those belonging to the culture medium. As a result, no further
investigation was done on this microbe.
2.7 Investigation of Anoxybacillus flavithermus (WK1)
Anoxybacillus flavithermus is a species of Gram-positive, rod shaped, alkaliphilic
and thermophilic bacteria that was first isolated from manure samples by Pikuta et
al. in 2000.69 These bacteria form dark yellow colonies due to accumulation of a
carotenoid pigment in their cell membrane.70 Different strains of A. flavithermus have
been isolated from thermophilic environments in New Zealand.69,70 This species has been
investigated for its production of moderately alkali-stable and heat-stable lignocellulolytic
enzymes, particularly cellusases and xylanases.71 These enzymes have numerous uses
in industrial applications, such as biobleaching of pulp and production of economical
and environmentally friendly biofuels. This is also the only species of Anoxybacillus
that produces these enzymes.71 In 2011, Liu et al. reported the isolation of the
metabolite cyclo(L-Gly-L-Pro) (24) from A. flavithermus strain SX-4 via bioassay-guided
fractionation of the culture broth.72 Compound 24 showed immunostimulatory effects in
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carp by significantly increasing phagocytic activity, superoxide anion production, serum
lysozyme activity and immune-related gene expression.72 Since then, no other metabolites
have been reported from this species.
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A. flavithermus strain WK1 was isolated from silica-rich geothermal well water in a drain
in the Wairakei Geothermal Power Station (Figure 2.5) located a few kilometres north of
Taupo. At the time of isolation, the water was at a temperature of 65 ◦C and a pH of 8.2.
Figure 2.5. Isolation site of A. flavithermus WK1.
Image courtesy of Matthew Stott, GNS Science.
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2.7.1 Isolation of a Known Compound from A. flavithermus
A 2 L culture of A. flavithermus was screened as described above. The 75% Me2CO/H2O
fraction from the culture filtrate was then further separated on a reversed-phase column
(HP20ss) using MeOH/ H2O mixtures of decreasing polarity with the final elution in
100% MeOH. 1H NMR spectra were obtained on all fractions and the spectrum of the final
MeOH fraction, CDB01 68E, showed aromatic signals belonging to a single compound.
1D and 2D NMR spectroscopic analysis of this fraction identified the compound as a
known β-carboline compound.
The molecular formula C13H10N2O was determined for CDB01 68E by positive ion
HRESIMS from the [M + H]+ adduct at m/z 211.0868 (m/z ∆ = 0.0002), requiring
10 double bond equivalents (DBEs). The 13C NMR spectrum contained 13 signals,
accounting for all the carbons in the molecule. The 1H NMR spectrum (DMSO−d6)
showed eight distinct proton signals that accounted for all 10 protons in the molecule.
An HSQC experiment confirmed the attachment of six protons to different carbon atoms
and three protons to one carbon atom, confirming the presence of a methyl group. This
indicated that the one remaining proton resonance was that of an exchangeable proton
(δH 11.90). Six aromatic proton signals were seen in the 1H NMR spectrum, with four
of these signals belonging to one spin system (δH 8.30, 7.81, 7.59, 7.30), and the other
two to another spin system (δH 8.51, 8.45). COSY correlations between aromatic protons
H-5 (δH 8.30; δC 121.9) and H-6 (δH 7.30; δC 120.2), H-6 and H-7 (δH 7.59; δC 129.0),
and H-7 and H-8 (δH 7.81; δC 113.1) established the connection between C-5 and C-8.
HMBC correlations from H-5 to C-7, H-6 to C-8, H-7 to C-5 and H-8 to C-6 confirmed
the presence of this connection and the presence of the four aromatic protons in the same
spin system (Figure 2.6).
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Figure 2.6. COSY and HMBC correlations confirming the connection between C-5 and
C-8 in CDB01 68E.
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HMBC correlations were also seen from H-6 and H-8 to non-protonated C-4b (δC 119.9)
along with HMBC correlations from H-5 and H-7 to non-protonated C-8a (δC 141.9).
These correlations confirmed the presence of a 1,2-disubstituted benzene substructure in
the molecule (Figure 2.7).
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Figure 2.7. COSY and HMBC correlations establishing the 1,2-disubstituted benzene
ring in CDB01 68E.
A strong HMBC correlation was observed between methyl CH3-11 (δH 2.79; δC 26.0) and
non-protonated deshielded C-10 (δC 201.4), suggesting the presence of an acetyl group
in the molecule. Furthermore, the highly deshielded exchangeable proton resonance
(δH 11.90) with no COSY correlations was indicative of a secondary amine moiety. A
database search was carried out using MarinLit and Scifinder Scholar in order to find
compounds that contained a disubstituted benzene ring, an acetyl group and a secondary
amine. The search yielded 1-acetyl-β-carboline (25) as a candidate compound with 10
double bond equivalents. Comparison of NMR data in the literature73 to those obtained
with 1-acetyl-β-carboline (Table 2.1) showed that the data were identical, confirming that
the compound isolated was 1-acetyl-β-carboline (25).
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2.7.2 Biological Activity of 1-Acetyl-β-carboline
β-Carbolines are a subclass of indole alkaloids that are commonly found in plants but
can also be produced by some animals and microorganisms. Due to the large number
of substituents and/or substitution patterns found in β-carbolines, these alkaloids display
a large variety of physiological and pharmacological properties.74 1-Acetyl-β-carboline
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Table 2.1. 1H (600 MHz) and 13C (150 MHz) NMR data for 1-acetyl-β-carboline (25)
(DMSO-d6)
13C 1H HMBC
Position δ (ppm) mult δ (ppm) mult J (Hz) COSY (1H to 13C)
1 136.0 C - - - - -
3 137.5 CH 8.51 d 4.8 4 1,4,4a
4 119.5 CH 8.45 d 4.8 3 1,3,4b,9a
4a 131.0 C - - - - -
4b 119.9 C - - - - -
5 121.9 CH 8.30 d 7.9 6 4a,7,8a
6 120.2 CH 7.30 t 8.1 5,7 4b,8
7 129.0 CH 7.59 t 7.7 6,8 5,8a
8 113.1 CH 7.80 d 7.5 7 4b,6
8a 141.9 C - - - - -
9 - - 11.90 s - - 4a,4b,8a,9a
9a 134.0 C - - - - -
10 201.4 C - - - - -
11 26.0 CH3 2.79 s - - 1,10
was first reported in 1977 from the plant Ailanthus malabarica.75 Since then, it has
been reported as a metabolite of a marine sponge, T. ignis,75 and several marine and
soil microorganisms.75–78 This compound has been shown to have cytotoxic effects on
brine shrimp but possesses only marginal antimicrobial activity.75 Shin et al. recently
described the antibacterial activity of 1-acetyl-β-carboline against methicillin-resistant
Staphylococcus aureus (MRSA).79 The study concluded that 1-acetyl-β-carboline and
ampicillin can act synergistically against MRSA and that this combination could aid in
reducing the emergence of MRSA in the future.79
Many β-carboline compounds function as monoamine oxidase (MAO) inhibitors.74 MAO
is an enzyme responsible for breaking down monoamine neurotransmitters such as
dopamine, serotonin, epinephrine, and many more. Inhibitors of this enzyme can thus be
used for treatments of psychiatric disorders such as depression and schizophrenia as they
prevent the breakdown of these neurotransmitters in the brain.80 1-Acetyl-β-carboline
is structurally similar to the β-carboline compounds norharman (26) and harman (27),
both of which are reversible inhibitors of human MAO.80 Consequently, CDB01 68E was
investigated for its MAO inhibitory activity in assays carried out at Environmental Science
and Research (ESR). However, no significant inhibition of the enzyme was observed.
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CDB01 68E was also submitted for testing at the School of Biological Sciences, VUW.
Assays were carried out against the 1A9 ovarian cancer, S. aureus, Escherichia coli and
Mycobacterium smegmatis cell lines. However, no significant cytotoxic or antimicrobial
activity was seen at any of the tested concentrations, including the highest concentrations
of 20 µM (for the 1A9 ovarian cancer cell lines) and 238 µM (for the bacterial cell lines).
2.8 Investigation of Chthonomonas calidirosea (T49)
Strain T49 was isolated from steam-heated soil at Hell’s Gate, Tikitere, in Rotorua
(Figure 2.8). At the time of isolation, the soil was at a temperature of 62.6 ◦C and a pH of
4.5. Phylogenetic studies carried out at GNS Science revealed that this strain represents a
new genus and species of Gram-negative, thermophilic bacteria. It was characterised and
named Chthonomonas calidirosea by Lee et al. in 2010.81 An investigation into the fatty
acid and lipid composition from the bacterial biomass was published by the same group
in 2011.82 No other publications on this species of bacteria were found in the literature.
A 20 L culture of T49 and cell mass extract were screened as described above. The 1H
NMR spectrum of the 75% Me2CO fraction from the culture filtrate was dominated by
resonances belonging to the antifoam (δH 3.3–4 ppm) used for culturing (Figure 2.9). To
separate the antifoam from possible masked metabolites, size-exclusion chromatography
(LH-20) was carried out on this fraction. 1H NMR analysis showed that the antifoam had
streaked through the column into all collected fractions. One of the LH-20 fractions
(CDB01 79C) was subjected to further fractionation on a DIOL column. However,
1H NMR analysis showed the antifoam to be the major component in all fractions
and confirmed that no further separation was achieved. Due to the difficult mid-polar
nature of the antifoam and the inability to separate it from any other compounds, further
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investigation on this microbe was discontinued.
Figure 2.8. Isolation site of T49.
Image courtesy of Matthew Stott, GNS Science.
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Figure 2.9. 1H NMR spectrum of the 75% Me2CO fraction from the culture filtrate of
T49 showing antifoam peaks from 3.3–4 ppm (600 MHz, CD3OD).
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2.9 Investigation of Pyrinomonas methylaliphatogenes
(K22)
Strain K22 was isolated from steam-heated soil on Mount Ngauruhoe (Figure 2.10)
located 25 km south of the southern shore of Lake Taupo. At the time of isolation, the soil
was at a temperature of 67.8 ◦C and a pH of 6.88. Phylogenetic studies carried out at GNS
Science revealed that this strain represents a new genus and species of Gram-negative,
thermophilic, moderately acidophilic bacteria (Figure 2.11). It was characterised and
named Pyrinomonas methylaliphatogenes by Crowe et al. in September 2013.83 The very
recent isolation of this new strain means that there has been no research reported on it in
the literature.
Figure 2.10. Isolation site of K22.
Image courtesy of Matthew Stott, GNS Science.
A 1 L culture of K22 and cell mass extract were screened as described above. The 1H
NMR spectrum of 75% Me2CO fraction from the culture filtrate showed no significant
peaks other than those belonging to the culture medium. As a result, no further
investigation was done on this microbe.
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Figure 2.11. TEM image showing latitudinal and longitudinal cross-section views of
K22 cell morphology (scale bar: 1 µm).
Image courtesy of Matthew Stott, GNS Science.
2.10 Investigation of P373
Strain P373 are Gram-positive, rod-shaped bacteria (Figure 2.12) that were isolated from
steam-heated soil found at Waikite in Rotorua (Figure 2.13). At the time of isolation,
the soil was at a temperature of 65 ◦C and a pH of 4.54. Phylogenetic studies carried
out at GNS Science revealed that this strain is phylogenetically dissimilar to others in
the microbial strain database and current studies are being undertaken to characterise and
name the new strain.
Figure 2.12. Light microscope phase contrast images of P373 cells (scale bar: 20 µm).
Image courtesy of Matthew Stott, GNS Science.
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A 3 L culture of P373 and cell mass extract were screened as described above. Some
unique proton resonances were seen in the 1H NMR spectrum of the 75% Me2CO fraction
(CDB01 85B) from the culture filtrate (highlighted in Figure 2.14). However, due to lack
of biomass, this microbe was not investigated further.
Figure 2.13. Isolation site of P373 and WKT50.2.
Image courtesy of Matthew Stott, GNS Science.
2.11 Investigation of WKT50.2
Strain WKT50.2 are Gram-positive bacteria (Figure 2.15) that were isolated from the
same site as P373 (Figure 2.13). Phylogenetic studies carried out at GNS Science
revealed that this strain is phylogenetically dissimilar to others in the microbial strain
database and current studies are being undertaken to characterise and name the new strain.
A 3 L culture of WKT50.2 and cell mass extract were screened as described above.
The 1H NMR spectrum of the 75% Me2CO fraction of the culture filtrate (CDB02 05E)
showed proton signals pertaining to one or more steroids. HPLC purification of this
32
BCH_CB_CHMCBMCHeCBeCHOCBOCHHCBHCHCBCH	CB	CH
CB
CH
_5f 
55B_
H_BB
Figure 2.14. 1H NMR spectrum of the 75% Me2CO fraction from the P373 culture
filtrate with unique resonances highlighted (600 MHz, CD3OD).
Figure 2.15. Cryogenic TEM of a WKT50.2 cell, showing the typical Gram-positive cell
wall structure (scale bar: 200 nm).
Image courtesy of Matthew Stott, GNS Science.
fraction and subsequent NMR and MS analysis revealed that it contained a mixture of two
steroids, cholic acid (28) and deoxycholic acid (29). However, NMR spectral comparison
with the 75% Me2CO fraction from the sterile culture medium showed that the steroids
were a component of the medium. It is thought that these steroids are an additive in the
peptone used for this medium.
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2.12 Conclusion
Over the course of this research, 10 different extremophilic microbes were screened, nine
of which are described above. For most of the strains, only a few milligrams were obtained
in the mid-polar fractions from 1 or 2 L of culture, with the majority of mass being from
culture medium components. This outcome was not surprising, as extremophiles often
produce low amounts of biomass.84 The lack of isolated biomass did, however, serve as a
major limitation. Subsequent identification of new compounds from the screen fractions
was difficult due to masking of the metabolite NMR signals by culture media signals and
sometimes, antifoam signals that would dominate the spectra. This made it difficult to
target new metabolites and purify any fractions further.
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Chapter 3
2,5-Diketopiperazines from Shewanella sp.
3.1 2,5-Diketopiperazines
2,5-Diketopiperazines (DKPs) (Figure 3.1) are the smallest cyclic dipeptides that result
from the condensation of two α-amino acids. They are abundant in nature and have been
isolated from fungi, bacteria, plants, processed foods and many other sources.85 These
small, conformationally constrained molecules contain a six-membered heterocycle in
which diversity can be introduced at up to four positions, with stereochemical control
at two positions. Moreover, they are resistant to proteolysis and mimic peptidic
pharmacophoric groups as they contain constrained amino acids. They contain two cis-
amide bonds and as a result possess two H-bond acceptor and two H-bond donor sites,
which allows them to bind to a wide variety of receptors.86 These characteristics make
them ideal for medicinal chemistry, where the unwanted physical properties of peptides
can cause challenges.
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Figure 3.1. General structure of a 2,5-DKP.
The DKP scaffold can also be synthesised easily by conventional methods owing to
its structural simplicity. The successful syntheses of many DKPs, which cover a wide
range of approaches to synthesise the DKP ring, have been extensively reviewed.85–87
DKPs have also been used as chiral catalysts and auxiliaries during synthesis due to their
structural and functional diversity, and their facile accessibility from chiral amino acids.85
Numerous naturally occuring and synthetic DKPs have been subjected to structure-
activity relationship (SAR) studies, which has led to the development of clinical drugs
such as Tadalafil (30), Aplaviroc (31), Retosiban (32) and Epelsiban (33), all of which
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contain the DKP scaffold.85 The majority of DKPs that have been isolated contain L-
amino acids but many DKPs that contain D-amino acids have also been characterised.
DKPs containing D-amino acids have often been isolated from bacteria, which is expected
as these amino acids are an abundant component of the peptidoglycan cell walls.88 The
DKP scaffold has often been found alone but also occurs embedded in many modified and
complex natural products. The amino acid proline is regularly found in DKPs due to its
ability to form a favoured cis-tertiary amide bond in the DKP ring with other amino acids,
which makes it prone to 2,5-DKP formation.85
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3.1.1 Biosynthesis of 2,5-DKPs
It was previously thought that the biosynthesis of all 2,5-DKPs was catalysed by
nonribosomal peptide synthetases (NRPSs) in microbes. Only recently has it come to
light that enzymes known as cyclodipeptide synthases (CDPSs) are also involved in the
biosynthesis of some DKPs, either as targets or as intermediates to other compounds.89
NRPSs are large multienzyme complexes made up of different modules, with each
module responsible for the incorporation of one amino acid into the final peptide.90 Each
module is divided further into domains that represent the enzymatic units responsible
for catalysing the individual steps of nonribosomal peptide synthesis. There are three
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essential domains. These are the adenylation domain (A) that recognises and activates
the substrate, the peptidyl carrier protein domain (T) that binds the activated substrate
through a thioester linkage via a phosphopantetheinyl arm, and the condensation domain
(C) that forms the peptide bond (Scheme 3.1). DKPs can be synthesised either by
dedicated NRPSs or as truncated side products during the synthesis of larger peptides,
with the former being responsible for the biosynthesis of majority of all DKPs.90 NRPSs
that are dedicated to DKP synthesis lack the thioesterase termination domain (TE) and
instead contain a C domain that cyclises the linear dipeptidyl thioester, which then releases
the DKP. During the synthesis of large peptides, spontaneous intramolecular cyclisation
can occur to form a DKP side product. In these DKPs, cyclisation is favoured when a
sterically constrained residue, such as a prolyl or N-methyl-amino acyl group, is present
to allow for a cis conformation of the peptide bond that is necessary for formation of
the DKP ring.90,91 For example, cyclomarazine A is released as a side product during
the biosynthesis of cyclomarin C (Scheme 3.1).92 DKPs synthesised by NRPSs can be
modified by accessory enzymes that are present in some domains. A range of chemical
modifications can be applied to the DKP before it is released by the NRPS. These include
configuration changes, indole prenylation as seen in tryprostatins, methylation (M) as
seen in fumitremorgins and many more.90,91
CDPSs are a recently described family of small enzymes that can synthesise various
cyclodipeptides (CDPs).89 These enzymes are unrelated to those of NRPSs and use
aminoacyl-tRNAs as substrates by hijacking them, thereby eliminating the need to
activate the amino acids.90,91 As a result, they are limited to the 20 L-amino acids that
are charged on tRNAs. CDPSs have also been associated with CDP-tailoring enzymes
that play a role in modifying the CDPs. Unlike NRPSs that can modify the DKP before
it is released, chemical modifications by tailoring enzymes can only be introduced into
CDPs after they have been produced by CDPSs.91 The first report of the characterisation
of a CDPS biosynthetic pathway for a CDP was that of an antibacterial and antitumour
compound, albonoursin, isolated from Streptomyces noursei in 2002.93 AlbC is the CDPS
that mainly produces cyclo(L-Phe-L-Leu), which is then converted to albonoursin by
the tailoring enzymes CDP oxidases albA and albB (Scheme 3.2). Since the discovery
of the albonoursin pathway, three more individual CDPS-dependent pathways have
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Scheme 3.1. NRPS biosynthesis of cyclomarin C and side product cyclomarazine A.
Enzymatic domain abbreviations: A, adenylation; T, thiolation (peptidyl carrier protein);
C, condensation; M, methyltransferase; and TE, thioesterase.
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Scheme 3.2. Biosynthesis pathways of a) albonoursin, b) pulcherrimin,
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been fully characterised for pulcherriminic acid from Bacillus subtilis, mycocyclosin
from Mycobacterium tuberculosis and cyclo(L-Trp-L-Trp)-Me/Me2 from Actinosynnema
mirum (Scheme 3.2), each with their own tailoring enzymes.89,90,94,95
3.1.2 Biological Activity of 2,5-DKPs
There have been an overwhelming number of reports on the isolation of both simple
and modified DKPs from various sources over the past few decades. These DKPs
have covered a variety of bioactivities ranging from antibacterial, antifungal, cytostatic
and quorum sensing activity to bioherbicidal, neuroprotective, cardiovascular and blood
clotting alteration, and many more. The different bioactivities of both simple and complex
DKPs have been extensively reviewed in the literature,85,86,96,97 and as a result, the
discussion below focusses on the antibiotic, cytostatic and quorum sensing activities of
some microbial proline and tryptophan based 2,5-DKPs that are relevant to the research
described in this thesis.
Antibiotic DKPs
Kumar et al. recently reported the isolation of cyclo(L-Leu-D-Pro) (34), cyclo(L-
Met-L-Pro) (35), cyclo(L-Phe-D-Pro) (36), cyclo(L-Phe-L-Pro) (37), cyclo(L-Tyr-L-
Pro) (38) and cyclo(D-Tyr-L-Pro) (39) from Streptomyces sp. strain N and found that
all compounds showed good activity against Staphylococcus aureus and B. subtilis
bacteria, and showed superior antifungal activity than the standard fungicide Bavistin
against Fusarium oxysporum, Rhizoctonia solani and Pencillium expansum fungi.98 All
compounds also showed inhibition of Aspergillus flavus and Candida albicans. The
highest antifungal activity of 2 µg/mL was exhibited by 37 against the plant pathogen
P. expansum. All compounds except 39 showed activity against E. coli, with 37 having
the lowest MIC of 8 µg/mL. DKPs 35, 36 and 37 also showed moderate inhibition
against Pseudomonas aeruginosa. DKP 38, also known as maculosin, has previously
been isolated from a Gram-negative bacterial strain 679-2 and showed no significant
antibiotic activity.99 However, when combined with other compounds isolated from the
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same strain, it showed synergistic activity against Aspergillus niger, M. smegmatis and
Saccharomyces cerevisiae. DKP 37 has also been isolated from Aspergillus fumigatus,
along with DKPs cyclo(L-Gly-L-Pro) (24), cyclo(L-Pro-L-Pro) (40), cyclo(L-Val-L-Pro)
(41), cyclo(L-Leu-L-4-Hyp) (42), cyclo(L-Phe-L-4-Hyp) (43) and cyclo(L-Leu-L-Pro)
(44).100 It was found that all the isolated compounds inhibited the growth of S. aureus
and Micrococcus luteus at the concentration of 2.9 mM. DKP 41 has been isolated
from several microbes including Pseudomonas aurantiaca, Streptomyces sp. H7372,
Psychrobacter sp., Chromocleista sp. and many others.101–104 It was also isolated from
Pseudomonas rhizosphaerae along with DKPs 37, 38, and 44.105 Antibacterial assays
revealed that 37 was active against Loktanella hongkongensis and Ruegeria sp. at 200
µg/mL and M. luteus and Bacillus cereus at 100 µg/mL. DKP 38 was active against
Ruegeria sp. at 200 µg/mL and 41 was active against L. hongkongensis at 200 µg/mL.
Both 37 and 43 have also been isolated from Lactobacillus plantarum and showed
antifungal activities against a range of fungi and yeasts including Aspergillus nidulans,
C. albicans and S. cerevisiae.106 The antifungal activity of some proline based 2,5-DKPs
against S. cerevisiae has previously been researched and was also briefly studied during
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this project, both of which are discussed in Section 3.4. The cyclo(L-Phe-D-4-Hyp) (45)
isomer of 43 has been isolated from Aureobasidium pullulans, Psychrobacter sp. and A.
fumigatus, with no reports of any significant antibiotic activity.107,108 The cyclo(L-Phe-
D-6-Hyp) (46) and cyclo(L-Phe-L-6-Hyp) (47) isomers of 43 have been isolated from
Chromocleista sp. but failed to show any activity against S. aureus when tested at 50
µg/mL.104 DKP 44 has also been isolated from Streptomyces sp. KH-614 and showed
activity against a range of fungi including C. albicans, A. fumigatus, R. solani at MIC
values ranging from 5–50 µg/mL, with the highest activity against Pyricularia oryzae
at 2.5 µg/mL.109 Both 37 and 44 have showed activity against vancomycin-resistant
enterococci (VRE) strains of bacteria at 25 and 12.5 µg/mL, respectively.110,111 It was also
reported that when combined, the two DKPs exhibited a synergistic effect against many
VRE, Gram-positive and Gram-negative bacteria.112 In 2003, five D-D DKPs, cyclo(D-
Phe-D-Pro) (48), cyclo(D-Leu-D-Pro) (49), cyclo(D-Val-D-Pro) (50), cyclo(D-Ile-D-Pro)
(51) and cyclo(D-Phe-D-4-Hyp) (52), were isolated from bacterial strains CF-20 and C-
148, which were associated with cultures of Pecten maximus.113 The L-L enantiomers
of these compounds were synthesised along with some D-L and L-D isomers and all
compounds were tested against the fish pathogen Vibrio anguillarum. All five isolated D-
D DKPs showed remarkable inhibitory activity against V. anguillarum with MIC values
ranging from 0.03–0.07 µg/mL, whereas the L-L enantiomers lacked activity altogether.
It was also found that when only one D-amino acid was present in the DKP, the activity
was not completely lost and the MIC values were 2–3 times higher than those of the D-D
isomers. This effect was seen in DKP 36, which had an MIC of 0.1 µg/mL. Cyclo(L-
Trp-L-Pro) (53), also known as brevianamide F, has been isolated from many sources
including Penicillium brevi-compactum and Streptomyces fungicidicus.114,115 DKP 53
isolated from Streptomyces sp. strain TN58 showed activity against M. luteus and S.
aureus.116 The cyclo(L-Trp-D-Pro) (54) isomer of 53 was recently isolated from the
endophytic fungus Penicillium sp. HS-3, with no report on its biological activity.117
Cyclo(L-Trp-L-Val) (55) and cyclo(L-Trp-L-Ala) (56) are tryptophan-containing 2,5-
DKPs that have been isolated from Roseobacter sp., with no report on their activity.118
DKP 56 has also been isolated from Eurotium herbariorum and showed weak activity
against Enterobacter aerogenes, B. subtilis, E. coli, P. aeruginosa and C. albicans.119
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Cytostatic DKPs
There have been very few reports of cytotoxic and cytostatic activities from simple proline
and tryptophan-containing DKPs. DKPs 24, 37, 38, 40, 44, cyclo(L-His-L-Pro) (57)
and cyclo(L-Thr-L-Pro) (58) have been tested against HT-29 colon cancer, MCF-7 breast
cancer and HeLa cervical cancer cell lines.120 DKP 38 only showed weak inhibition of
MCF-7, whereas DKP 37 weakly inhibited the growth of all three cell lines with IC50
values of 4.04, 6.53 and 2.92 mM, respectively. No activity was reported for the other
DKPs. DKP 37 also induced apoptotic cell death in the HT-29 cells, which was later found
to be mediated by a caspase cascade.121 These results suggested that 37 could potentially
inhibit the growth of tumours in vivo. DKP 44 has also been tested against K562, HL-60,
and U937 leukemia cell lines, and at a concentration of 100 µg/mL, it exerted significant
growth inhibitory rates of 95, 91 and 93%, respectively.111
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Cyclo(L-Trp-L-Pro) (53), cyclo(L-Trp-L-Val) (55) and cyclo(L-Trp-L-Ala) (56) are
precursors to numerous modified and complex DKPs that have been isolated from
microbes. However, it is mainly the modified versions of DKP 53 that have exhibited
cytostatic activities and, therefore, some of these are discussed here. DKP 53 serves
as a biosynthetic precursor to many DKPs including fumitremorgins, verruculogen,
tryprostatins, spirotryprostatins and cyclotryprostatins. Fumitremorgins A (59) and B (60)
are prenylated and annulated analogues of 53 that were initially isolated from A. fumigatus
Fres. in 1971.122 Fumitremorgin C (61) is another analogue that was isolated from a
different strain of A. fumigatus in 1977.123 Verruculogen (62), which is structurally similar
to 59 with a hydroxyl group in place of a prenyl group, was isolated from Penicillium
verruculosum in 1972.124 Compounds 59, 60 and 62 were all isolated as toxins that were
capable of producing severe tremors in mice when administered orally.122–124 In 1990,
a dihydroxylated version (63) of 61 was isolated from A. fumigatus DSM 790 with no
report on its biological acitvity.125 Compounds 60, 61, 62 and 63 were later re-isolated
from A. fumigatus BM939 along with demethoxyfumitremorgin C (64) and tryprostatins
A (65) and B (66), which are non-annulated versions of 61 and 64, respectively.126 All the
isolated compounds were tested for their inhibitory activity on the cell cycle progression
of mouse tsFT210 cells and each compound showed inhibition at the M phase of the cell
cycle (Table 3.1), which makes these compounds useful as potential anticancer agents
as they cause mitotic arrest. Subsequent studies showed that 65 specifically inhibits cell
cycle progression at the M phase by disrupting microtubule assembly whereas 66 is a non-
specific inhibitor of the cell cycle.127 Compounds 65 and 61 have also showed potential
as reversers of breast cancer resistance protein (BCRP)-mediated multidrug resistance by
inhibiting the ATP-dependent drug transport activity of BCRP.128,129 Spirotryprostatins
A (67) and B (68) are spiro-annulated and prenylated analogues of 53 that were also
isolated from A. fumigatus BM939.130 The same production strain was screened again
and led to the isolation of cyclotryprostatins A–D (69–72), which are mono-prenylated
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and annulated analogues.131 All six compounds showed inhibition of the cell cycle
progression of mouse tsFT210 cells at the G2/M phase (Table 3.1).130,131
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Table 3.1. IC50 values of some complex DKPs against the cell cycle progression of
mouse tsFT210 cells126,130,131
Compound IC50 (µM) Cell Cycle Phase
Fumitremorgin B (60) >209.0 M
Fumitremorgin C (61) 14.0 M
Verruculogen (62) >196.0 M
12,13-Dihydroxyfumitremorgin C (63) >243.0 M
Demethoxyfumitremorgin C (64) 1.78 M
Tryprostatin A (65) 78.7 M
Tryprostatin B (66) 18.8 M
Spirotryprostatin A (67) 197.5 G2/M
Spirotryprostatin B (68) 14.0 G2/M
Cyclotryprostatin A (69) 5.6 G2/M
Cyclotryprostatin B (70) 19.5 G2/M
Cyclotryprostatin C (71) 23.4 G2/M
Cyclotryprostatin D (72) 25.3 G2/M
In 2008, spirotryprostatins C–E (73–75) were isolated from A. fumigatus Fres. along
with two hydroxylated derivatives (76 and 77) of 60 and 13-oxoverruculogen (78).132 All
compounds were evaluated for their cytotoxic activities against MOLT-4, A549, HL-60,
and BEL-7420 cancer cell lines. Compounds 73 and 74 showed weak activities against all
four cell lines with IC50 values ranging from 17.5–68.8 µM, whereas 75 showed moderate
activity against MOLT-4, HL-60 and A-549 cells at 3.1, 2.3 and 3.1 µM, respectively.
Compounds 76 and 77 showed moderate activities against all cell lines with IC50 values
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ranging from 3.4–11.6 µM. Compound 78 also showed moderate activity against HL-60
cells at IC50 1.9 µM, with weak activity against the other cell lines (IC50 16.9–25.7 µM).
Spirotryprostatin F (79) was recently isolated from a marine isolate of A. fumigatus and
showed phytoregulating activity, with no other biological activity reported.133
DKPs with Quorum Sensing Activity
Quorum sensing (QS) is the process by which bacteria communicate with each other using
self-produced small diffusible signalling molecules known as autoinducers (AIs), which
help mediate gene expression simultaneously in all members of the population.134 The
concentration of secreted AI molecules in a particular environment correlates directly
to the abundance of bacteria in the vicinity. Once a certain concentration threshold of
AIs is reached, the communicating bacteria undertake a coordinated change in their gene
expression profiles. These changes lead to phenotypes such as secondary metabolite
production, bioluminescence, virulence factor production, motility, biolfilm formation
and many others.134,135 The coordinated nature of these changes allows these prokaryotes
to behave like multicellular organisms and exhibit complex intercellular interactions.
There are three main classes of AIs that are used by bacteria for QS and these differ
depending on the type of bacteria. The first class comprises of acylated homoserine
lactones (AHLs) (80), also termed AI-1, which are generally produced by Gram-negative
bacteria and that diffuse through the cellular plasma membrane.134 This system consists
of two regulatory genes, a luxI homologue that encodes the AHL synthase and a luxR
homologue that encodes the AHL sensor peptide. Once a threshold concentration
of AHLs is reached, it is sensed and bound by the cytoplasmic LuxR-type peptide
and this complex either activates or inactivates target gene(s) in the operon, thereby
producing phentoypic changes in the bacterial population. This system was initially
discovered in 1970 in Vibrio fischeri and was found to play a role in the bioluminescence
of these bacteria.136 This was also the first report of QS as a method of bacterial
intercellular communication. The second class of AIs is seen primarily in Gram-positive
bacteria and comprises of small modified peptides, which are usually produced from the
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cleavage of precursor oligopeptides and are then transported out of the cell via an ATP
binding cassette transporter.135 In this system, once the secreted peptide concentration
is sufficient, it is recognised by a membrane-bound sensor kinase protein, which causes
phosphorylation of a response regulator protein and leads to transcription of the target
gene(s). The sensor proteins in Gram-positive QS are usually highly specific to their
peptide AIs. The third class of AIs, termed AI-2, consists of a furanosyl borate diester
(81) and a non-borate diester (82), which are produced by an AI-2 LuxS-type synthase
that is encoded by a luxS homologue.135 This homologue is present in almost half of
all sequenced bacterial genomes, and thus, AI-2 production can be found in both Gram-
negative and Gram-positive bacteria. The A1-2 signalling system can also be used in
conjuction with other signalling systems. These characteristics of AI-2 have suggested
that it could be a method of interspecies communication, whereas the more conserved
AI-1 and peptide signalling systems serve as intraspecies communication.
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As mentioned above, QS is used by pathogenic bacteria to exert their virulence on hosts.
Therefore, disruption of this communication, known as quorum quenching, is an attractive
target for the development of an anti-infective compounds. Interestingly, some 2,5-DKPs
have showed inhibition of QS in microbes, whereas others have been shown to activate
QS. In 1999, Holden et al. evaluated the activity of DKPs 37, 38, 35, 41, 44, cyclo(L-
Ala-L-Pro) (83), and cyclo(∆Ala-L-Val) (84) against several LuxR-based AHL biosensor
strains.137 All DKPs except 35 showed concentration-dependent activation of the AHL
biosensor in E. coli (pSB401) but at much lower concentrations than the native AHL.
Competition studies showed that these DKPs may be competing with the AHL for the
same LuxR binding site as they were able to antagonise the AHL-mediated induction
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of bioluminescence, with 41 having the highest inhibitory activity. DKP 35, on the other
hand, showed agonistic affects and was the most potent activator of the biosensor in E. coli
(pSB401). DKP 41 was also able to induce pigment production in the Chromobacterium
violaceum AHL reporter strain. In a bioassay against Serratia liquefaciens, it was found
that DKPs 38 and 84 were able to reduce the swarming ability of these bacteria. DKP
44 isolated from Achromobacter xylosoxidans showed inhibition of aflatoxin production
from Aspergillus parasiticus by repressing transcription of the genes involved.138 DKP
37 isolated from four Vibrio spp. showed induction of the ompU genes in all species
and also induced the ctx genes in Vibrio cholerae.139 These genes encode virulence factor
production and thus play a role in the pathogenicity of these bacteria. Collectively, these
studies showed that DKPs could not only modulate the activity of LuxR-based QS, but
could also represent a new class of AIs as they are capable of mimicking the actions of
AHLs in Gram-negative bacteria. Following these reports, Campbell et al. published
an elaborate study in 2009 in which they designed a synthetic library of 23 DKPs, which
included those previously reported as QS agonists and antagonists to confirm their activity
and mode of action.140 In order to directly validate reported results, all biosensor strains
used in assays were the same as previously reported. Surprisingly, the results conflicted
with previous reports as it was found that none of the naturally occuring DKPs exhibited
either agonistic or antagonistic activities in any tested strains. When tested in V. fischeri,
several non-native DKPs were capable of inhibiting bioluminescence but did not do so
through interaction with LuxR, which was another contradiction to previous reports. The
study concluded that while DKPs can affect QS-related outcomes, they do not interact
with LuxR-type proteins and that previous studies may have suffered contamination
issues. Since this study, there have been more reports of QS-interfering DKPs. DKP
24 was recently shown to inhibit many QS-dependent phenotypes in P. aeruginosa by
competing with the AHL for the LasR receptor protein, which is responsible for inducing
many phenotypes when bound to the AHL.141 Abed et al. recently reported that DKPs
37, 44 and cyclo(L-Ile-L-Pro) (85) reduced QS-dependent bioluminescence in E. coli
(pSB401) in the presence of AHL, and DKPs 37 and 85 also showed inhibition of QS-
dependent pigment production in C. violaceum.142 Although DKPs may not exhibit their
actions via interaction with LuxR-type peptides, they remain interesting compounds for
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use in quorum quenching and it remains to be seen whether they do in fact represent a
new class of signalling molecules.
3.2 The Genus Shewanella
Bacteria from the genus Shewanella, the sole genus in the Shewanellaceae family, are
Gram-negative, facultatively anaerobic, rod-shaped microbes that possess polar flagella
for motility.143 The majority of members of this genus are psychrotolerant, with many
being true psychrophiles, while others can grow at higher temperatures.144 These bacteria
are widely distributed throughout the world, especially in aquatic environments.144 The
type of environments they are found in can range from freshwater lakes to deep cold-water
marine environments to hydrothermal vents.145 They have been isolated from various
sources including fish, algae, ground meat, oil emulsions, milk, cream and many more.146
They can be free-living or symbionts.147 Shewanella spp. produce trimethylamines and
hydrogen sulfide and are thus associated with the rotting of fish.143 The first report of a
Shewanella sp. was in 1931 by Derby and Hammer from putrefied butter, although the
bacterium was tentatively named Achromobacter putrefaciens.148 It was only in 1985 that
the genus was redesignated to Shewanella by MacDonell and Colwell.149 Since then, there
have been over 50 different species described (Table 3.2). Multiple unidentified strains
of Shewanella have also been researched.
Numerous species of Shewanella have been investigated for their enzymes over the past
two decades. To date, various enzymes have been characterised from these bacteria
including alkaline phosphatases, reductases, pepsin (Shewasin A), dehydrogenases,
proteases, endonucleases and many more.150–155 In 2008, Bodor et al. reported the
presence of the luxS gene that codes for the synthase enzyme of the AI-2 group of
signalling molecules (discussed in Section 3.1.2), in all tested Shewanella strains.156
The production of AI-2 was confirmed by a Vibrio harveyi luminescence bioassay, as
these bacteria can sense AI-2, which then causes luminescence. All tested Shewanella
strains were able to induce luminescence in V. harveyi. The study confirmed the presence
of luxS related signalling in Shewanella. Another important characteristic of bacteria
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Table 3.2. Taxonomic classification of species from the genus Shewanella from order
Alteromonadales
Order Family Genus Species
Alteromonadales
Alteromonadaceae . . . . . . . . .
Colwelliaceae . . . . . . . . .
Ferrimonadaceae . . . . . . . . .
Idiomarinaceae . . . . . . . . .
Moritellaceae . . . . . . . . .
Pseudoalteromonadaceae . . . . . . . . .
Psychromonadaceae . . . . . . . . .
Shewanellaceae Shewanella
abyssi litorisediminis
algidipiscicola livingstonensis
algae loihica
amazonensis marina
aquimarina marinintestina
arctica marisflavi
atlantica massilia
baltica morhuae
basaltis olleyana
benthica oneidensis
canadensis pacifica
chilikensis pealeana
colwelliana piezotolerans
corallii pneumatophori
decolorationis profunda
denitrificans psychrophila
dokdonensis putida
donghaensis putrefaciens
fidelis saccharophilus
fodinae sairae
frigidimarina schlegeliana
gaetbuli sediminis
gelidimarina seohaensis
glacialipiscicola spongiae
hafniensis surugensis
halifaxensis taiwanensis
haliotis upenei
hanedai vesiculosa
indica violacea
irciniae waksmanii
japonica woodyi
kaireitica xiamenensis
from this genus is that they are capable of dissimilatory reduction of various heavy
metals and other toxic substances by using them as electron acceptors during respiration,
thereby detoxifying these substances.147 Metals and compounds that can be reduced by
Shewanella bacteria include elemental sulphur, nitrate, nitrite, thiosulphate, manganese
and iron oxides, vanadium, chromium, neptunium and many more.147 These diverse
metabolic capabilities make Shewanella bacteria important for carbon cycling and of
potential use in the bioremediation of contaminated environments.147
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3.2.1 Pathogenicity of Shewanella spp.
In 1990, Simidu et al. isolated a Shewanella sp. from a red alga and found that it produced
tetrodotoxin (86), a potent neurotoxin that is lethal to many organisms, and called the
isolate Shewanella algae.157 No other species of Shewanella has been reported to produce
this toxin. Both S. algae and S. putrefaciens are known as opportunistic pathogens in
humans and marine organisms.144 The occurrence of Shewanella infections in humans
are rare and, in the past, were only reported in patients who lived in warm temperatures.
However, reports of bacterial infections in humans from both warm and cool temperatures
has been increasing over the last few decades.143 Shewanella infections that have been
reported manifest symptoms such as bacteremia, septicemia, meningitis, ear infection,
respiratory distress, pneumonia, and many more.146 However, both S. algae and S.
putrefaciens are susceptible to common antibacterials. Although infections are caused
by both species, S. algae is more pathogenic in humans.144 It has also been suggested that
the production of 86 by this species could play a role in its higher pathogenicity.144
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It was recently reported that at warm temperatures, a soybean protein concentrate diet
caused intestinal disorders in farmed Atlantic salmon.158 The causal fish pathogens were
later identified as V. harveyi and Yersinia ruckeri (NIWA — Unpublished), both of which
pose a large threat to fish farming industries. An assay was recently carried out at
Callaghan Innovation to assess the pathogenicity of several strains of Shewanella towards
V. harveyi and Y. ruckeri. The results (Figure 3.2) showed that nine strains (Table 3.3)
inhibited the growth of both pathogens. V. harveyi and Y. ruckeri are both known to use
QS for pathogenicity.159 Therefore, it is possible that the Shewanella strains exhibit their
inhibitory activity by disrupting the QS of these bacteria. Further studies into this project
are being carried out at NIWA, Callaghan Innovation and VUW. These results may have
important implications for the aquaculture industry in New Zealand.
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Vibrio harveyi Yersinia ruckeri
Figure 3.2. Shewanella assay against V. harveyi (left) and Y. ruckeri (right).
Image courtesy of Jason Ryan, Callaghan Innovation.
Table 3.3. List of tested strains and their activity against V. harveyi and Y. ruckeri
Active against
Isolate no. Species (>99% similarity) Source V. harveyi Y. ruckeri
541 S. fidelis South China Sea No No
544 Photobacterium sp. Tarakihi No No
545 S. marinitestina/S. sairae Tarakihi Yes Yes
546 S. marinitestina/S. sairae Tarakihi Yes Yes
547 S.baltica Bluenose Yes Yes
548 S. halifaxensis Bluenose Yes Yes
549 S. halifaxensis Jack Mackerel No No
550 S. baltica Jack Mackerel Yes Yes
551 S. baltica Jack Mackerel Yes Yes
552 Vibrio sp. Scorpion Fish No No
566 S. halifaxensis Blue Warehou Yes Yes
567 S. marinitestina/S. sairae Blue Warehou Yes Yes
568 S. marinitestina/S. sairae Blue Warehou Yes Yes
569 S. marinitestina/S. sairae Blue Warehou No No
3.2.2 Reported Bioactive Metabolites from Shewanella spp.
Since the isolation of the first species of Shewanella, there have been very few reports
of bioactive metabolites from these bacteria. As mentioned above, the production of
neurotoxin 86 by S. algae was one of the first reports of a bioactive metabolite from
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this genus.157 The fatty acids 2-hydroxymyristic acid (87) and cis-9-oleic acid (88) were
isolated from S. oneidensis by Bhattari et al. in 2007.160 Both compounds showed
potential for use as antifoulants. Many species of Shewanella produce various fatty
acids including eicosapentaenoic acid (EPA) (89), an omega-3 fatty acid (essential fatty
acid) that cannot be produced by humans and must be obtained nutritionally. In 2007,
Nishida et al. showed that EPA may have an antioxidative function within its producer, S.
marinintestina.161
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In 1997, putrebactin (90), which is a siderophore, was isolated from S. putrefaciens.162
Siderophores are metal-specific chelating compounds that are secreted by microbes
to sequester iron, especially by those undergoing low iron stress such as in marine
environments where iron solubility is poor but essential for almost all life processes.
Another siderophore, avaroferrin (91), was isolated recently from S. algae and was found
to inhibit the swarming ability of Vibrio alginolyticus by binding iron in a form that is
inaccessible to these bacteria.163 In November 2013, Gu et al. published a study that
focussed on the extracellular metabolite production of S. baltica, and its role in food
spoilage.164 Four DKPs, cyclo(L-Gly-L-Pro) (24), cyclo(L-Phe-L-Pro) (37), cyclo(L-
Leu-L-Pro) (44) and cyclo(L-Leu-L-Leu) (92), were isolated from the supernatant of S.
baltica strain 00C and were evaluated for their role in food spoilage using fish muscle
juice. The study concluded that 37 had the highest spoilage capability after 24 hours.
These results suggested that the DKPs could be acting as QS signalling molecules by
increasing the spoilage capability of S. baltica. Since the members of this genus have
relatively unexplored secondary metabolic profiles, they are attractive targets for natural
product research.
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3.3 Isolation of Secondary Metabolites from Shewanella
sp.
Shewanella sp. strain 569 was isolated from the intestines of Blue Warehou (Seriolella
brama) found in the Cook Strait (Table 3.3). A 16S sequence carried out at Callaghan
Innovation revealed that the strain is >99% phylogenetically similar to S. marinintestina
and S. sairae. However, ongoing chemotaxonomic studies are being carried out to identify
the species. During this research, two cultures (a total of 33 L) of Shewanella sp. strain
569 obtained from Callaghan Innovation were studied as described in Chapter 2.
3.3.1 Compounds from the 75%Me2CO/H2O fraction
The 75% Me2CO/H2O fraction from the culture filtrate showed proton NMR signals
pertaining to secondary metabolites and was further separated on a reversed-phase
column (HP20ss). Subsequent fractionation using size-exclusion (LH-20) and normal
phase (DIOL) chromatography led to the isolation of one compound, CDB01 77C.
Reversed-phase HPLC purification on another DIOL fraction resulted in the isolation of a
second pure compound, CDB01 80C (Scheme 3.3). Both compounds, CDB01 77C and
CDB01 80C, were then characterised mainly by MS and NMR.
Indole-3-carboxaldehyde
The molecular formula C9H7NO was determined for CDB01 77C by positive ion
HRESIMS from the [M + H]+ adduct at m/z 146.0597 (m/z ∆ = -0.0003), requiring
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Shewanella sp., 33L supernatant
HP20 (Me2CO/H2O)
30% 75% 100%
CDB01_57A CDB01_57B CDB01_57C
CDB01_83C CDB01_83D CDB01_83E
HP20ss (MeOH/H2O)
40% 50% 100%1-9 10-17 18-27 28-33 34-42 43-52 53-64 65-72 73-82 83-88
CDB01
_67B
CDB01
_67C
LH-20 (100% MeOH/H2O)
CDB01
_67A
CDB01
_67F
CDB01
_67G
CDB01
_67H
CDB01
_67I
CDB01
_67D
CDB01
_67E
CDB01
_67J
CDB01
_63G
CDB01
_63E
CDB01
_63F
1-27 28-32 33 34-37 38-43 44-49 50-59
CDB01
_73F
CDB01
_73G
CDB01
_73H
CDB01
_73I
CDB01
_73D
CDB01
_73E
CDB01
_73J
60-73 74-81 82-114
CDB01
_73M
CDB01
_73K
CDB01
_73L
DIOL (Hexane (H)/Ethyl acetate (EA)/MeOH)
100% H 25% EA/H 50% EA/H 100% EA 25% MeOH/EA 50% MeOH/EA 100% MeOH
CDB01_77A CDB01_77B CDB01_77C CDB01_77D CDB01_77E CDB01_77F CDB01_77G
Indole-3-
carboxaldehyde
4.8 mg
CDB01_80C
Cyclo(L-Trp-L-Pro)
1.9 mg
C18 HPLC (45%-100% MeCN/H2O)
Scheme 3.3. Isolation of indole-3-carboxaldehyde and cyclo(L-Trp-L-Pro).
seven DBEs. The 13C NMR spectrum contained five protonated (δC 187.4, 125.0, 123.6,
122.4, 113.1) and four non-protonated carbon resonances (δC 139.7, 138.9, 125.6, 120.0)
assigned from HMBC correlations through neighbouring protons. One of the carbon
resonances was highly deshielded and attached to a proton (δH 9.89; δC 187.4), and was
indicative of an aldehyde group in the compound.
The 1H NMR spectrum (CD3OD) contained resonances that accounted for six of the seven
protons in the molecule. An HSQC experiment confirmed the attachment of all six protons
to carbons, indicating the presence of one exchangeable proton. Four aromatic proton
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signals (δH 8.16, 7.48, 7.28, 7.24) with similar coupling constants were seen in the 1H
NMR spectrum. COSY correlations between aromatic protons H-4 (δH 8.16; δC 122.4)
and H-5 (δH 7.24; δC 123.6), H-5 and H-6 (δH 7.28; δC 125.0), and H-6 and H-7 (δH
7.48, δC 113.1) established the connection between C-4 and C-7. HMBC correlations
from H-4 to C-6, H-5 to C-7 and H-6 to C-4 and H-7 to C-5 confirmed the presence of
this connection. HMBC correlations were also seen from H-5 and H-7 to non-protonated
C-3a (δC 125.6) along with HMBC correlations from H-4 and H-6 to non-protonated C-
7a (δC 138.9). These correlations confirmed the presence of a 1,2-disubstituted benzene
substructure in the molecule (Figure 3.3).
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Figure 3.3. COSY and HMBC correlations establishing the 1,2-disubstituted benzene
substructure in indole-3-carboxaldehyde.
Aromatic proton H-2 (δH 8.11; δC 139.7) showed HMBC correlations to non-protonated
C-3 (δC 120.0), C-3a and C-7a. These correlations suggested that the 1,2-disubstituted
ring was an indole moiety in the compound. This accounted for the one exchangeable
proton in the compound. Furthermore, HMBC correlations were seen from aldehyde
proton H-8 (δH 9.89; δC 187.4) to C-3 and C-3a, suggesting that the aldehyde was
substituted at C-3 of the indole (Figure 3.4). This structure fits with the molecular formula
and also contained seven DBEs, confirming that the elucidated structure was correct.
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Figure 3.4. HMBC correlations establishing the indole moiety and the connection to the
aldehyde group in indole-3-carboxaldehyde.
The structure showed that a known indole alkaloid, indole-3-carboxaldehyde (93), was
isolated. The recorded NMR data (Table 3.4) were identical to those in the literature.165
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Table 3.4. 1H (600 MHz) and 13C (150 MHz) NMR data for indole-3-carboxaldehyde
(93) (CD3OD)
13C 1H HMBC
Position δ (ppm) mult δ (ppm) mult J (Hz) COSY (1H to 13C)
2 139.7 CH 8.11 s - - 3,3a,7a
3 120.0 C - - - - -
3a 125.6 C - - - - -
4 122.4 CH 8.16 d 7.7 5 6,7a
5 123.6 CH 7.24 t 8 4,6 3a,7
6 125.0 CH 7.28 t 7.3 5,7 4,7a
7 113.1 CH 7.48 d 8.2 6 3a,5
7a 138.9 C - - - - -
8 187.4 CH 9.89 s - - 3,3a
Cyclo(L-Trp-L-Pro)
The positive ion HRESIMS for CDB01 80C showed an [M + H]+ adduct at m/z 284.1392
(m/z ∆ = -0.0002), suitable for a molecular formula of C16H17N3O2 and 10 DBEs. The
13C NMR spectrum contained 11 protonated (δC 125.6, 122.6, 119.9, 119.8, 112.2, 60.0,
57.2, 45.9, 29.2, 29.1, 22.5) and five non-protonated carbon resonances (δC 170.7, 167.4,
138.0, 128.7, 109.4) that were assigned from HMBC correlations through neighbouring
protons. Two of the carbon resonances were highly deshielded (δC 170.7 and δC 167.4)
and were indicative of two ester or amide groups in the compound.
The 1H NMR spectrum (CD3OD) contained resonances that accounted for 15 of the 17
protons in the molecule. An HSQC experiment confirmed the attachment of all 15 protons
to carbons, indicating the presence of two exchangeable protons. Four aromatic proton
signals H-4 (δH 7.58; δC 119.8), H-5 (δH 7.01; δC 119.9), H-6 (δH 7.09; δC 122.6) and
H-7 (δH 7.33, δC 112.2) with similar coupling constants, along with another aromatic
proton H-2 (δH 7.10; δC 125.6) were seen in the 1H NMR spectrum with the same COSY
and HMBC correlations that were observed for indole-3-carboxaldehyde (93). These
correlations suggested that there was an indole moiety in the compound (Figure 3.5).
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This also accounted for one of the two exchangeable protons in the compound.
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Figure 3.5. COSY and HMBC correlations establishing indole in cyclo(L-Trp-L-Pro).
Long range COSY correlations between methylene H2-8 (δH 3.32; δC 29.2) and H-2
indicated that C-8 was directly attached to C-3 (δC 109.4) of the indole ring. HMBC
correlations from H2-8 to C-2, C-3 and C-3a (δC 128.7) confirmed this substitution on
the indole. Furthermore, H2-8 also showed HMBC correlations to two more carbon
atoms, protonated C-9 (δH 4.42; δC 57.2) and non-protonated, highly deshielded C-14
(δC 167.4). A strong COSY correlation between H2-8 and H-9 confirmed that C-9 was
directly connected to C-8, and a weak HMBC correlation from H-9 to C-14 confirmed that
C-14 was connected to C-9 (Figure 3.6). The downfield chemical shift of C-14 suggested
that it was part of either an ester or an amide group. However, the two oxygen atoms in
the molecule were already accounted for as part of carbonyl groups, which meant that
C-14 was part of an amide group.
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Figure 3.6. COSY and HMBC correlations establishing the connections between C-3
and C-14 in cyclo(L-Trp-L-Pro).
A separate spin system was established from COSY correlations between deshielded
methylene H2-15 (δH 3.46 (a), 3.27 (b); δC 45.9) and H2-16 (δH 1.69 (a), 1.47 (b); δC
22.5), and H2-16 and H2-17 (δH 1.97 (a), 0.93 (b); δC 29.1) which indicated connections
between C-15 and C-17. A strong HMBC correlation from H-17(a) to C-15, and weak
correlations from H-15(a) and H-17(b) to C-16 confirmed this connection. H-17(b) also
showed a weak correlation to C-12 (δH 4.00; δC 60.0) and H-12 showed strong COSY
correlations to both H-17(a) and (b) confirming the presence of a bond between the two
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carbons. A weak HMBC correlation was also seen from H-12 to non-protonated, highly
deshielded C-11 (δC 170.7), whose chemical shift was indicative of an amide group. This
correlation suggested that C-11 was directly connected to C-12 (Figure 3.7).
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Figure 3.7. COSY and HMBC correlations establishing the connections between C-15
and C-11 in cyclo(L-Trp-L-Pro).
Thus far, all the carbon, nitrogen and non-exchangeable proton atoms in the molecule had
been accounted for, with one exchangeable proton unaccounted for. Eight of the 10 DBEs
had also been established in the compound. Since the NMR spectra showed no evidence
of more double bonds, the remaining two DBEs required two more rings in the molecule.
Methylene CH2-15 should be connected to one of the two amide nitrogen atoms, as it
was deshielded. It could only be connected to the amide containing C-14, as a connection
to the other amide would result in an isolated structure. Similarly, C-12 should also be
connected to the same amide group. This resulted in a five-membered ring in the molecule
(Figure 3.8), accounting for one more DBE.
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Figure 3.8. Connection between the two established substructures for
cyclo(L-Trp-L-Pro).
The last remaining connection was that from C-9 to the amide containing C-11, which
formed a six-membered ring accounting for the tenth DBE. A weak HMBC correlation
from H-9 to C-11 confirmed this connection. This means that the exchangeable proton
was also connected to the nitrogen atom in this amide group. CH-12 and CH-9 were both
in α-positions to a nitrogen atom and a carbonyl group, which explained their downfield
chemical shifts.
The elucidated structure showed that a known 2,5-DKP consisting of amino acids
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tryptophan and proline had been isolated. The NMR data for the D-D and L-L isomers of
DKPs are identical but differ from their D-L and L-D counterparts. The specific rotations
of all four stereoisomers also differ from each other and this property can be used to
determine which one is present. Thus, the configuration of centres C-9 and C-12 were
determined by comparison of specific rotation measurements and NMR data (Table 3.5)
with published data. The NMR, MS and MS/MS data, along with an [α]25D of -70 (c = 0.1,
MeOH) (lit. [α]25D = -48, c = 0.06, MeOH) confirmed that cyclo(L-Trp-L-Pro) (53) was
isolated.166,167
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Table 3.5. 1H (600 MHz) and 13C (150 MHz) NMR data for cyclo(L-Trp-L-Pro) (53)
(CD3OD)
13C 1H HMBC
Position δ (ppm) mult δ (ppm) mult J (Hz) COSY (1H to 13C)
2 125.6 CH 7.10 s - 8 3,3a,7a
3 109.4 C - - - - -
3a 128.7 C - - - - -
4 119.8 CH 7.58 d 8 5 6,7a
5 119.9 CH 7.01 t 7 4,6 3a,7
6 122.6 CH 7.09 t 7 5,7 4,7a
7 112.2 CH 7.33 d 8.2 6 3a,5
7a 138.0 C - - - - -
8 29.2 CH2 3.32 m - 2,9 2,3,3a,9,14
9 57.2 CH 4.42 m - 8 3,8,11,14
11 170.7 C - - - - -
12 60.0 CH 4.00 ddd 10.9,6.3,1.8 17(a),(b) 11,17
14 167.4 C - - - - -
15 45.9 CH2 3.46(a) m - 15(b),16(a),(b) 16
3.27(b) m - 15(a),16(a),(b) -
16 22.5 CH2 1.69(a) m - 15(a),15(b),16(b),17(a) -
1.47(b) m - 15(a),15(b),16(a),17(b) -
17 29.1 CH2 1.97(a) m - 12,16(a),16(b),17(b) 15
0.93(b) m - 12,16(b),17(a) 12,16
3.3.2 Compounds from the 30%Me2CO/H2O fraction
The 30% Me2CO/H2O fraction from the culture filtrate showed proton NMR signals
that were indicative of secondary metabolites along with those pertaining to the cul-
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ture medium. To separate the compounds from the medium, size-exclusion (LH-20)
chromatography was carried out on this fraction. The resulting fractions contained
mixtures of similar compounds and were further separated by reversed-phase (HP20ss)
chromatography, followed by HPLC purification. MS and NMR analysis on all fractions
revealed that 13 more known 2,5-DKPs were isolated (Scheme 3.4).
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Scheme 3.4. Isolation of more 2,5-DKPs from the 30% fraction of Shewanella sp..
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Cyclo(L-Phe-L-4-Hyp)
The molecular formula C14H16N2O3 was confirmed for CDB02 34B by the presence of
an HRESIMS [M + H]+ adduct at m/z 261.1237 (m/z ∆ = 0.0003), requiring eight DBEs.
The 13C NMR spectrum contained 12 distinct resonances (δC 171.3, 167.0, 137.4, 131,
129.4, 128.1, 68.4, 58.3, 57.6, 55.2, 38.8, 38.0). Two of the carbon resonances (δC 171.3
and δC 167.0) had chemical shifts similar to those seen for the two carbonyl groups in
cyclo(L-Trp-L-Pro) (53), which suggested that this compound was another 2,5-DKP. This
accounted for two nitrogen and two oxygen atoms in the molecule.
The 1H NMR spectrum (CD3OD) contained resonances that accounted for 14 protons
in the molecule. An HSQC experiment confirmed the attachment of all 14 protons to
carbons, indicating the presence of two exchangeable protons. A deshielded methylene,
CH2-3 (δH 3.70 (a), 3.29 (b); δC 55.2) and a highly deshielded methine group CH-4 (δH
4.28; δC 68.4) along with another methylene CH2-5 (δH 2.06 (a), 1.36 (b); δC 38.8),
all belonging to the same spin system were observed in the 1H NMR spectrum. COSY
correlations between H-3(a) and H-4, and H-4 and H-5(b) established the connection
between C-3 and C-5. Furthermore, HMBC correlations from H-5(a) to C-3 and C-
4, H-3(a) to C-5, and H-4 to C-3 confirmed this connectivity. No other COSY or
HMBC correlations were evident for a carbon atom connected to C-3 and C-4. The
deshielded nature of methylene CH2-3 suggested that it was connected to an amide
nitrogen. Similarly, the highly deshielded nature of the methine suggested that C-4 was
directly connected to a hydroxyl group (Figure 3.9). This accounted for the final oxygen
atom and one exchangeable proton in the molecule.
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Figure 3.9. COSY and HMBC correlations establishing the connections between C-3
and C-5 in cyclo(L-Phe-L-4-Hyp).
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HMBC correlations were observed from H-3(a), H-5(b) and H-4 to methine CH-6
(δH 4.37; δC 58.3), along with COSY correlations between methylene H2-5 and H-6,
confirming that C-6 was directly connected to C-5. The presence of HMBC correlations
from H-5(b) and H-6 to amide C-7 (δC 171.3) extended the substructure to a 4-
hydroxyproline moiety in the molecule. This substructure also accounted for the final
exchangeable proton. Furthermore, HMBC correlations were seen from methine H-9 (δH
4.48; δC 57.6) to C-1, C-6 and C-7, confirming that C-9 was directly attached to amide
C-1 (δC 167.0) and to the nitrogen atom of amide C-7 (Figure 3.10). This substructure
accounted for four DBEs in the molecule.
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Figure 3.10. COSY and HMBC correlations establishing amino acid 4-hydroxyproline
in cyclo(L-Phe-L-4-Hyp).
The substructure above confirmed that another 2,5-DKP had been isolated. A multiplet
that integrated for five protons was seen in the aromatic region (δH 7.27, 7.24, 7.22),
which was characteristic for a monosubstituted benzene ring. This also accounted for
the four remaining DBEs. Monosubstituted benzene ring protons H-12/16 (δH 7.24; δC
131.0) showed HMBC correlations to methylene C-10 (δH 3.17; δC 38.0) suggesting that
C-10 was directly connected to C-11 (δC 137.4) of the ring. HMBC correlations from
methylene H2-10 to C-11 and C-12/16 confirmed this connection. A COSY correlation
from H2-10 to H-9 and HMBC correlations from H2-10 to C-9 and C-1 established the
connection to the DKP ring (Figure 3.11).
13
14
15
16
11
12
H
H
H
H
H
10
6
N
1
O
7
O
HN
9
H
COSY
HMBC
HH
5
4
3
OH
Figure 3.11. COSY and HMBC correlations establishing the connections between the
monosubstituted benzene ring and 4-hydroxyproline in cyclo(L-Phe-L-4-Hyp).
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The elucidated structure showed that a known 2,5-DKP consisting of phenylalanine and
4-hydroxyproline had been isolated. The configurations of centres C-4, C-6 and C-9 were
established based on comparisons of obtained NMR (Table 3.6) and specific rotation data
with those in the literature. An [α]25D of -98 (c = 1.77, MeOH) (lit. [α]
20
D = -90, c =
1.0, EtOH) confirmed that cyclo(L-Phe-L-4-Hyp) (43) was isolated.106,168 MS/MS data
obtained for this compound were also consistent with those in the literature.169
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Table 3.6. 1H (600 MHz) and 13C (150 MHz) NMR data for cyclo(L-Phe-L-4-Hyp) (43)
(CD3OD)
13C 1H HMBC
Position δ (ppm) mult δ (ppm) mult J (Hz) COSY (1H to 13C)
1 167.0 C - - - - -
3 55.2 CH2 3.70(a) dd 13,5.1 3(b),4 1,5,6
3.29(b) d 13 3(a) 4,5,6
4 68.4 CH 4.28 t 4.7 3(a),5(b) 3,6
5 38.8 CH2 2.06 dd 13,5.9 5(b),6 3,4
1.36(b) ddd 24.7,12.6,4.7 4,5(a),6 6,7
6 58.3 CH 4.37 ddd 12,5.9,1.6 5(a),5(b) 5,7
7 171.3 C - - - - -
9 57.6 CH 4.48 td 5.4,1.9 10 1,6,7,10,11
10 38.0 CH2 3.17 m - 9 1,9,11,12,16
11 137.4 C - - - - -
12 131.0 CH 7.24 m - -† 10,14
13 129.4 CH 7.27 m - -† 11
14 128.1 CH 7.22 m - -† 12,16
15 129.4 CH 7.27 m - -† 11
16 131.0 CH 7.24 m - -† 10,14
†COSY correlations could not be resolved due to overlapping of peaks.
Cyclo(L-Leu-L-4-Hyp)
Positive ion HRESIMS analysis of CDB02 35B revealed an [M + H]+ adduct at m/z
227.1392 (m/z ∆ = 0.0002), which corresponded to the molecular formula C11H18N2O3
and four DBEs. The 13C NMR spectrum contained 11 distinct resonances (δC 173.1,
169.0, 69.1, 58.7, 55.1, 54.6, 39.3, 38.1, 25.8, 23.3, 22.2). The 1H NMR spectrum
(CD3OD) contained resonances that accounted for 16 protons in the molecule. An HSQC
experiment confirmed the attachment of all 16 protons to carbons, indicating the presence
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of two exchangeable protons. The presence of two highly deshielded carbon atoms,
C-1 (δC 169.0) and C-7 (δC 173.1), which were indicative of amides, along with two
characteristic deshielded methines, CH-6 (δH 4.53; δC 58.7) and CH-9 (δH 4.18; δC
54.6), suggested that this compound was another 2,5-DKP. A deshielded methylene CH2-
3 (δH 3.65 (a), 3.43 (b); δC 55.1), a highly deshielded methine CH-4 (δH 4.47; δC 69.1)
and another methylene CH2-5 (δH 2.28 (a), 2.08 (b); δC 38.1) were seen belonging to
the same spin system and were indicative of 4-hydroxyproline as one of the amino acids.
This accounted for all four DBEs in the molecule.
Two methyl doublets, CH3-12 (δH 0.96; δC 23.3) and CH3-13 (δH 0.95; δC 22.2), were
seen in the 1H NMR spectrum. HMBC correlations from both methyl groups to methine
CH-11 (δH 1.90; δC 25.8) established a gem-dimethyl group in the second amino acid.
COSY correlations from H-11 to methylene CH2-10 (δH 1.91 (a), 1.51 (b); δC 39.3)
established a connection from C-11 to C-10. COSY correlations between H2-10 and
methine H-9 established the connection to the DKP ring, which was confirmed by HMBC
correlations from H-11 and H2-10 to C-9 (Figure 3.12).
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Figure 3.12. COSY and HMBC correlations establishing leucine in
cyclo(L-Leu-L-4-Hyp).
The established structure showed that a 2,5-DKP containing leucine and 4-hydroxyproline
had been isolated. The NMR (Table 3.7), MS and MS/MS data, along with an [α]25D of
-123 (c = 1.15, MeOH) (lit. [α]20D = -108, c = 1.0, EtOH) confirmed that cyclo(L-Leu-L-
4-Hyp) (42) was isolated.100,168,169
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Table 3.7. 1H (600 MHz) and 13C (150 MHz) NMR data for cyclo(L-Leu-L-4-Hyp) (42)
(CD3OD)
13C 1H HMBC
Position δ (ppm) mult δ (ppm) mult J (Hz) COSY (1H to 13C)
1 169.0 C - - - - -
3 55.1 CH2 3.65(a) dd 13,4.5 3(b),4 6
3.43(b) d 13 3(a) 4,5,6
4 69.1 CH 4.47 t 4.2 3(a),5(b) 3,6
5 38.1 CH2 2.28 dd 13.3,6.5 5(b),6 3,4
2.08(b) m - 4,5(a),6 6,7
6 58.7 CH 4.53 dd 11.2,6.5 5(a),5(b) 5,7
7 173.1 C - - - - -
9 54.6 CH 4.18 m - 10(a),10(b) 1,10,11
10 39.3 CH2 1.91(a) m - 9,10(b),11 1,9,11,12,13
1.51(a) m - 9,10(a),11 1,9,11,12,13
11 25.8 CH 1.90 m - 10(a),10(b),12,13 9,10
12 23.3 CH3 0.96 d 6.4 11 10,11,13
13 22.2 CH3 0.95 d 6.4 11 10,11,12
Cyclo(Phe-4-Hyp)
Detection of an [M + H]+ adduct at m/z 261.1237 (m/z ∆ = 0.0003) indicated a
molecular formula of C14H16N2O3 for CDB02 35E. The 13C and 1H NMR spectra showed
aromatic peaks pertaining to a monosubstituted benzene ring, which was indicative of
phenylalanine. The other amino acid was identified as 4-hydroxyproline due to the
presence of two methylene groups and a highly deshielded methine group in the same
spin system. These data suggested that the compound isolated was a stereoisomer of
43. The MS/MS data for this compound were also similar to those obtained for 43. The
configuration of the amino acids was not established due to the presence of an impurity
in the fraction, which meant that specific rotation measurements would be inconclusive.
However, comparison of the recorded NMR data with those in the literature revealed that
either the L-D or the D-L stereoisomer of cyclo(Phe-4-Hyp) (94) had been isolated.107
HN
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Cyclo(Phe-6-Hyp)
An [M + H]+ adduct was observed for CDB02 36G at m/z 261.1241 (m/z ∆ = 0.0007)
that was suitable for a molecular formula of C14H16N2O3, which was the same as DKP
43. The NMR spectra showed evidence that phenylalanine was one of the amino acids.
Three methylene groups (δH 1.94; δC 19.2 and δH 1.98-2.24; δC 36.8), one of which
was deshielded (δH 3.66; δC 45.8), were observed in the same spin system, suggesting
that the other amino acid was a derivative of proline. COSY correlations between all
three methylene groups, along with an HMBC correlation from one methylene (δH 1.98-
2.24; δC 36.8) to the DKP ring carbon (δC 86.6) confirmed this substructure. The
DKP ring carbon belonging to the proline moiety was highly deshielded and also non-
protonated, which confirmed that a hydroxyl group was directly connected to it. Hence,
a regioisomer of 43, cyclo(Phe-6-Hyp) (95) that contains 6-hydroxyproline instead of 4-
hydroxyproline was isolated. The fraction was a mixture of compounds and therefore its
specific rotation could not be measured, and hence the configuration of the amino acids
was not established. The obtained NMR data was compared with published data, and it
was concluded that either the L-L or the D-D enantiomer had been isolated.104 MS/MS
analysis on this compound showed five product ions, which are presented below.
Table 3.8. MS/MS data for cyclo(Phe-6-Hyp)
m/z Calc. m/z Fragment m/z ∆
HN
N
O
O OH
91.0544
120.0807 86.0602
148.0741
105.0702
95
148.0741 148.0757 C9H10NO -0.0016
120.0807 120.0808 C8H10N -0.0001
105.0702 105.0699 C8H9 0.0003
91.0544 91.0542 C7H7 0.0002
86.0602 86.0600 C4H8NO 0.0002
Cyclo(Phe-Pro)
Analysis of the [M + H]+ adduct observed at m/z 245.1289 (m/z ∆ = 0.0004) for
CDB02 36I established a molecular formula of C14H16N2O2. The 1H NMR spectrum
showed peaks that were similar to those seen for DKP 43. The three major differences
were the loss of one oxygen atom, the presence of a methylene group instead of a
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methine and an upfield shift of the DKP ring methine in the proline moiety. These
differences suggested that this compound contained proline instead of 4-hydroxyproline.
The recorded spectroscopic data confirmed that the compound isolated was cyclo(Phe-
Pro) (96).169 Owing to an impurity of the fraction, its specific rotation could not be
measured, and hence the configuration of the amino acids was not established. However,
comparison of the obtained NMR data to the literature indicated that either the L-L or
the D-D enantiomer had been isolated.106 Unfortunately, a majority of the compound
degraded before a 13C NMR spectrum could be obtained, and as a result, the presented
13C NMR spectrum appears more crowded than the 1H NMR spectrum (see Appendix D).
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Cyclo(L-Phe-D-Pro)
The HRESIMS [M + H]+ adduct at m/z 245.1283 (m/z ∆ = -0.0002) afforded the
molecular formula C14H16N2O2 for CDB02 37A. The 13C and 1H NMR spectra showed
aromatic peaks pertaining to a monosubstituted benzene ring that were characteristic for
phenylalanine. The other amino acid was identified as proline due to the presence of three
methylene groups in the same spin system. The recorded spectroscopic data, along with
an [α]25D of +61 (c = 0.28, MeOH) (lit. [α]
20
D = +67, c = not reported, MeOH), were in
agreement with published data and confirmed that the compound isolated was another
known 2,5-DKP, cyclo(L-Phe-D-Pro) (36).169,170
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Cyclo(Phe-Leu)
The observation of an [M + H]+ adduct at m/z 261.1596 (m/z ∆ = -0.0002) indicated a
molecular formula of C15H20N2O2 for CDB02 30F. The NMR spectra showed evidence
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that phenylalanine was one of the amino acids. The other amino acid was identified as
leucine due to the presence of two methyl doublets, a methine and a methylene group in
the same spin system. The NMR, MS and MS/MS data confirmed that the compound
isolated was another known 2,5-DKP, cyclo(Phe-Leu) (97).167 Due to insufficient mass
of the compound, specific rotation measurements were not obtained. Although the
configuration of the amino acids was not known, spectroscopic data of the compound
suggested that it was either the L-L or the D-D enantiomer.171
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Cyclo(L-Leu-L-Pro)
HRESIMS data for CDB02 35I showed an [M + H]+ adduct at m/z 211.1445 (m/z ∆ =
0.0004) that was consistent with a molecular formula of C11H18N2O2. The NMR spectra
showed peaks that were very similar to those seen for DKP 42, with the three major
differences being the loss of one oxygen atom, the presence of a methylene group instead
of a methine and an upfield shift of the DKP ring methine in the proline moiety. These
differences suggested that this compound contained proline instead of 4-hydroxyproline.
The specific rotation of -127 (c = 0.89, MeOH) (lit. [α]20D = -136, c = 0.12, EtOH) and
spectroscopic data were all consistent with published data and confirmed that cyclo(L-
Leu-L-Pro) (44) was isolated.100,169,172
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Cyclo(L-Val-L-Pro)
The presence of an [M + H]+ adduct at m/z 197.1290 (m/z ∆ = 0.0005) suggested
a molecular formula of C10H16N2O2 for CDB02 35D. The 13C and 1H NMR spectra
showed three methylene groups that were indicative of proline. Two methyl doublets
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(δH 0.94; δC 16.7 and δH 1.09; δC 18.8) and a methine septet (δH 2.49; δC 30.0) were
also observed in the same spin system. COSY and HMBC correlations between these
groups established an isopropyl group in the second amino acid. The methine proton
of the isopropyl group showed a COSY correlation to a DKP ring methine proton (δH
4.03; δC 61.4) and also showed HMBC correlations to carbon atoms within the DKP ring,
establishing a direct connection between the two. Altogether, these correlations confirmed
that the second amino acid was valine. The NMR, MS and MS/MS data, along with an
[α]25D of -150 (c = 0.04, MeOH) (lit. [α]
22
D = -143, c = 0.2, EtOH), were in agreement
with those in the literature and confirmed that the compound isolated was another known
2,5-DKP, cyclo(L-Val-L-Pro) (41).100,101,173
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Cyclo(L-Tyr-L-Pro)
An [M + H]+ adduct that was observed at m/z 261.1233 (m/z ∆ = -0.0001) for
CDB02 30E revealed a molecular formula of C14H16N2O3, which was isomeric with
DKP 43. The NMR spectra showed evidence that proline was one of the amino acids.
However, there was no indication of a monosubstituted benzene ring in the molecule,
which suggested that this compound was a regioisomer of 43. Two proton doublets (δH
7.04; δC 131.8 and δH 6.70; δC 115.9) that integrated for two protons each were observed
in the aromatic region of the 1H NMR spectrum. COSY correlations between the two sets
of methines and HMBC correlations to the surrounding non-protonated aromatic carbons
(δC 157.8, 127.8) established a 1,4-disubstituted benzene ring in the molecule. One of
the carbon atoms in the 1,4-disubstituted benzene ring was highly deshielded (δC 157.8),
which suggested that it was substituted with a hydroxyl group. An HMBC correlation
from the aromatic protons (δH 7.04) to a methylene group (δH 3.09 (a), 3.02 (b); δC
37.5), along with COSY correlations between the methylene and a DKP ring methine
proton (δH 4.37; δC 57.9) established a connection between the two. Collectively, these
correlations confirmed that the other amino acid was tyrosine. All recorded data including
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an [α]25D of -59 (c = 0.25, MeOH) (lit. [α]
24
D = -58, c = 0.50, MeOH) were consistent with
published data and confirmed that cyclo(L-Tyr-L-Pro) (38) had been isolated.173–175
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Cyclo(L-Trp-D-Pro)
HRESIMS analysis of CDB02 31D showed an [M + H]+ adduct at m/z 284.1388 (m/z
∆ = -0.0006) that corresponded to the molecular formula C16H17N3O2, which was the
same as DKP 53. The MS/MS and NMR data for this compound were also very similar
to those obtained for 53, with major differences visible in the chemical shifts of the DKP
ring methines, which suggested that it was a stereoisomer of 53. The MS, NMR and
specific rotation data ([α]25D of +94 (c = 0.05, MeOH)) (lit. [α]
20
D = +68, c = 0.1, MeOH)
suggested that the cyclo(L-Trp-D-Pro) (54) stereoisomer had been isolated.117
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Cyclo(Trp-Ala)
The molecular formula C14H15N3O2 was determined for CDB02 28D from the HRES-
IMS [M + H]+ adduct at m/z 258.1242 (m/z ∆ = 0.0005). The 13C and 1H NMR
spectra showed aromatic peaks pertaining to an indole moiety, which was indicative of
tryptophan. Additionally, one methyl doublet (δH 0.40; δC 19.5) that showed a COSY
correlation to one of the 2,5-DKP ring methine protons (δH 3.58; δC 49.7) was observed
in the NMR spectra, which was indicative of alanine as the second amino acid. The
MS and NMR data confirmed that the compound isolated was another known 2,5-DKP,
cyclo(Trp-Ala) (98). MS/MS analysis on this compound only showed one product ion,
which is presented below. Owing to an insufficient amount of the compound, specific
rotation measurements could not be carried out. Despite the unknown configuration of
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the amino acids, recorded spectroscopic data indicated that either the L-L or the D-D
enantiomer had been isolated.176
Table 3.9. MS/MS data for cyclo(Trp-Ala)
m/z Calc. m/z Fragment m/z ∆
HN
NH
O
O
HN
130.0646
98
130.0646 130.0651 C9H8N -0.0005
Cyclo(Trp-Val)
The [M + Na]+ adduct at m/z 308.1369 (m/z ∆ = 0.0000) was observed by HRESIMS
for CDB02 28I and afforded a molecular formula of C16H19N3O2. The NMR spectra
showed evidence that tryptophan was one of the amino acids. The other amino acid was
identified as valine due to the presence of two methyl doublets and a methine group in the
same spin system. The MS and NMR data were in agreement with those published for
cyclo(Trp-Val) (99). MS/MS analysis on this compound only showed one product ion,
which is presented below. The configuration of the amino acids could not be established
due to the small amount of compound isolated. However, comparison of the obtained
NMR data to those in the literature suggested that either the L-L or the D-D enantiomer
had been isolated.177
Table 3.10. MS/MS data for cyclo(Trp-Val)
m/z Calc. m/z Fragment m/z ∆
HN
NH
O
O
HN
130.0634
99
130.0634 130.0651 C9H8N -0.0017
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3.4 Biological Testing at VUW
As discussed in Section 3.1.2, simple DKPs have shown inhibition against a variety of
fungi, with activities ranging from moderate to potent. The mechanism of action for this
activity has not fully been elucidated, but some research has been done in the past using
the yeast Saccharomyces cerevisiae. In 1996, cyclo(L-Arg-D-Pro) (100) was isolated
from Pseudomonas sp. IZ208 as a chitinase inhibitor.178 Chitinase is an enzyme that
hydrolyses chitin, which is a linear polymer of N-acetylglucosamine and is an essential
component in the cell walls of fungi. S. cerevisiae are known to use chitinases during
cell separation, whereas C. albicans have been suggested to utilise these enzymes when
undergoing morphological changes from the non-pathogenic yeast form to the pathogenic
filamentous form.179 Shortly after its isolation, in vivo tests on DKP 100 showed, as
expected, that it inhibited the separation of daughter cells in cultures of S. cerevisiae
and prevented the progression of C. albicans from yeast to the infective form.180 It was
also found that while cell separation was inhibited, no effect was observed on the growth
of both yeasts. Following these results, Houston et al. investigated the crystal structure of
DKP 100 in complex with the enzyme and found that it exerts its activity by mimicking
a reaction intermediate (101).179 The group went on to explore the activities of similar
DKPs 24, 38, 57, and cyclo(L-Arg-L-Pro) (102) in cultures of S. cerevisiae and when
in complex with chitinase.181 The study concluded that DKP 57 had the highest cell
separation inhibitory activity in S. cerevisiae, albeit with a low IC50 of 1.1 mM for
chitinase inhibition (calculated through a fluorescence-based assay for chitinase), and
that the cyclo(Gly-L-Pro) residue alone is sufficient for binding family 18 chitinases and
exerting this inhibitory activity, which can be altered by changing the non-proline residue.
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The studies described above focussed only on simple proline DKPs and their inhibition
of cell separation in S. cerevisiae, with no proper results reported on growth inhibition.
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As a result, DKPs 42, 43 and 44 were submitted for yeast chemical genetic profiling
using wild-type S. cerevisiae to establish their activities, in addition to a mutant deletion
strain library to identify any other modes of action. These three DKPs differ from
those previously tested not only in the non-proline residue but two also contain a 4-
hydroxyproline residue, which could potentially affect their antifungal activity. Due
to unforeseen circumstances such as machine malfunction and inavailability, only
preliminary results were available for inclusion in this thesis. For the initial growth assay,
all three DKPs were tested against wild-type S. cerevisiae (BY4741) at concentrations of
30, 45, 60, 75, 90, 120, 150 and 180 µM. The results (Figure 3.13, 3.14, 3.15) showed that
at the highest concentration of 180 µM, all three compounds failed to exhibit significant
acitvity (p>0.05). The growth curve for DKP 43 (Figure 3.14) shows that at 30 µM,
inhibition was observed after 17 hours of incubation. However, this observation was
attributed to an anomaly of the plate reader and should not be considered accurate.
Figure 3.13. Growth curve for cyclo(L-Leu-L-4-Hyp) (42) against wild-type S.
cerevisiae.
S. cerevisiae are known to contain an extensive network of membrane-bound pumps,
known as the pleiotropic drug resistance network, whose function is to eject drugs out
of the cell as a defense mechanism.54 Thus, these efflux pumps may prevent some
compounds from reaching concentrations that affect growth. It is possible that the three
DKPs did not exhibit activity in the wild-type strain due to the presence of these pumps
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Figure 3.14. Growth curve for cyclo(L-Phe-L-4-Hyp) (43) against wild-type S.
cerevisiae.
Figure 3.15. Growth curve for cyclo(L-Leu-L-Pro) (44) against wild-type S. cerevisiae.
and as a result, they will be tested in a drug efflux pump knockout strain (∆pdr), which
could potentially result in inhibitory activity. Another possibility is that the DKPs are
only active at millimolar concentrations similar to those reported in studies carried out by
Houston et al. on other DKP compounds.181 Consequently, the three DKPs will also be
tested at higher concentrations in order to establish their activities, if any, and will then be
subjected to screening against the mutant deletion library. These results could potentially
contribute to the understanding of SAR for this class of compounds as antifungals.
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Chapter 4
Concluding Remarks
The marine and extremophilic environments continue to host various unique microbes
that are yet to be investigated for their secondary metabolite production. As a result,
they represent attractive targets for natural product research. During the course of this
study, 10 extremophilic microbes were screened using an adapted version of the existing
screening protocol at VUW. The protocol was adapted to screen liquid microbial cultures
instead of organic extracts. Seven extremophilic microbes yielded very low amounts of
biomass, which was primarily made up of culture media components. Moreover, the
NMR signals of potentially important compounds were masked by these components, a
problem that is not encountered when dealing with marine invertebrates and macroalgae.
These two limitations made it difficult to identify secondary metabolites in any fractions.
The addition of antifoam to one of the bulk cultures proved to be another issue. The
antifoam used in the culturing process was of mid-polar nature, which caused it to elute
along with secondary metabolites of interest and also masked their NMR signals. In the
future, to overcome these limitations, only bulk cultures without added antifoam should
be screened so as to minimise the masking of secondary metabolites.
Investigation of the thermophilic bacteria Anoxybacillus flavithermus resulted in the
isolation of 1-acetyl-β-carboline (25) from the 75% fraction of the culture filtrate. This
compound was tested for its antimicrobial, anticancer and MAO activity but did not show
any activity at the highest tested concentrations. A detailed investigation of the marine
extremophile Shewanella sp. led to the isolation of a known indole alkaloid, indole-3-
carboxaldehyde (93), and 14 known 2,5-DKPs (36, 38, 41–44, 53, 54, 94–99). This
class of compounds has previously been reported to have significant antifungal activity,
however, the mechanism has not fully been elucidated. Consequently, DKPs 42, 43 and
44 were submitted for yeast chemical genetic profiling using Saccharomyces cerevisiae to
establish their modes of action. However, all three compounds failed to show significant
inhibitory activity at concentations up to 180 µM in the preliminary assay. This research
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also concluded that 2,5-DKPs do not play a role in attenuating the growth of V. harveyi
as this strain was inactive in an assay carried out at Callaghan Innovation (discussed in
Section 3.2.1). It is important to note that the majority of compounds were isolated from
the 30% fraction of the Shewanella sp. culture filtrate. This result illustrated that all three
crude fractions from a screen should be investigated further, as in this case, only two
compounds were isolated from the 75% fraction. Altogether, the outcomes of this study
demonstrated the successful use of the adapted screening method for isolating secondary
metabolites from microbial cultures.
The compounds isolated during this research are all known and in order to prevent this
from recurring, an important direction to consider in terms of future work towards this
project would be to develop a 2D-NMR screening tool similar to the one developed by
Dr. Northcote’s group at VUW for screening sponge extracts.52,53,56 The screening tool
consists of a COSY, HSQC or HMBC mask that is generated by the addition of several
screens and is then overlaid on the screen fraction from the organism of interest. This
allows the user to distinguish between correlations pertaining to primary metabolites or
known compounds and those belonging to novel secondary metabolites. The screening
tool would ideally also include suitable blank cultures and antifoams to allow for
elimination of these signals. Another avenue would be to investigate extremophiles that
have been co-cultured with other microbes to see if this evokes novel/different secondary
metabolite production. Finally, a proper investigation on higher amounts of cell mass of
the microbes used in this research would be interesting as it could lead to the isolation of
novel compounds that were masked and therefore overlooked during this study.
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Chapter 5
Experimental
5.1 General Experimental
NMR spectra were obtained using a Varian DirectDrive spectrometer equipped with a
triple resonance HCN cryogenic probe operating at 600 MHz for 1H and 150 MHz for
13C nuclei. The chemical shifts of 13C and 1H spectra were referenced to the residual
solvent peaks (D2O: δH 4.79; CD3OD: δC 49.0, δH 3.31; CDCl3: δC 77.0, δH 7.26;
DMSO-d6: δC 39.5, δH 2.50). All NMR solvents were purchased from Aldrich with
the exception of deuterated methanol, which was purchased from Cambridge Isotope
Laboratories Inc. HRESIMS results were obtained from an Agilent 6530 Q-TOF mass
spectrometer equipped with an Agilent 1260 HPLC for solvent delivery utilising a
JetStreamTM electrospray ionisation source in positive mode. Water and MeCN solvents
were both made up as 5 mM solutions with ammonium formate. CID was performed using
nitrogen as collision gas at various energies (10-40, arbitrary units). Optical rotations were
measured at 25 ◦C using a Rudolph Research Analytical Autopol II polarimeter operating
at the emission wavelength of a sodium lamp (589 nm), with concentrations given in
g/100 mL.
Normal-phase column chromatography was performed using Supelco Discovery R© DSC-
DIOL functionalised silica: 3-(2,3-Dihydroxy-propoxy)-propyl-silica (Diol). Reversed-
phase column chromatography was performed using Supelco Diaion R© HP20 and HP20ss
poly(styrene-divinylbenzene) (PSDVB) resins. Size-exclusion chromatography was
performed using Sephadex R© LH-20 media. Two separate HPLC systems were used,
the first using a Rainin Dynamax SD-200 solvent delivery system with 25 mL pump
heads and a Varian Prostar 335 photodiode array detector for UV/Vis detection. The
second HPLC system was an Agilent Technologies 1260 Infinity HPLC equipped with a
quaternary pump, a thermostatted column compartment and diode array detector (DAD).
Following the DAD, a QuicksplitTM flow splitter directs 5% of the flow to an Agilent
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380-evaporative light scattering detector (ELSD) with 95% of the flow directed towards
collection. For HPLC purification, reversed-phase C18 analytical (Phenomenex Prodigy,
4.6 x 250 mm, 5 µm particle size) or semi-preparative (Phenomenex Prodigy, 10.0 x 250
mm, 10 µm particle size) columns were used. For all HPLC runs, the UV/Vis detector
was set to monitor at wavelengths of 210 and 280 nm.
All solvents used were HPLC-grade (purchased from Fisher Scientific) with the exception
of hexanes and dichloromethane, which were Optima R© grade. Water was distilled prior
to use and in the case of HPLC the water was further filtered through a membrane with a
pore size of 0.45 µm before use. Solvent compositions used are all reported as % vol/vol.
TLC analyses were performed using Machery-Nagel Polygram R© Sil G/UV254 plates and
developed in 10% MeOH in dichloromethane. TLC plates were then visualised under UV
light (λ = 254 nm and 350 nm) and then by dipping in 5% conc. H2SO4 in methanol
(v/v%) followed by 0.1% vanillin in ethanol (w/v%) and heated for analysis.
5.2 Screening Protocol for Microbial Cultures
The following protocol was used for screening cultures of NGM11.1 (3 L), NGM22.9 (1
L), WAP10.3.2 (1 L), WC14 (2 L), K22 (1 L), P373 (3 L) and WKT50.2 (3 L), which were
obtained from GNS Science, as well as T49 (20 L), which was obtained from Callaghan
Innovation.
The liquid culture was filtered using celite and filter paper to separate the supernatant from
any existing cell mass. The filtered supernatant was then passed through a 50 mL HP20
column that had been washed with 150 mL of Me2CO and MeOH and pre-equilibrated
in 150 mL H2O. The column was then eluted with 150 mL portions of i) H2O, ii) 30%
Me2CO/H2O, iii) 75% Me2CO/H2O and iv) 100% Me2CO. The 100% Me2CO fraction
was concentrated in vacuo. The 30% and 75% fractions were backloaded onto 30 mL and
15 mL HP20 columns, respectively. The columns were then eluted with 90 mL and 45
mL 100% Me2CO, respectively. The fractions were then concentrated in vacuo. The cell
mass and celite were extracted overnight twice, first in 80% MeOH and second in 100%
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MeOH. The second extract was passed through a pre-equilibrated 25 mL HP20 column,
followed by the first extract. The extracts were then collected together and cyclic loaded
onto the same column. The column was then eluted with 75 mL portions of i) H2O,
ii) 30% Me2CO/H2O, iii) 75% Me2CO/H2O and iv) 100% Me2CO. The 100% Me2CO
fraction was concentrated in vacuo. The 30% and 75% fractions were backloaded onto 15
mL and 10 mL HP20 columns, respectively. The columns were then eluted with 45 mL
and 30 mL 100% Me2CO, respectively. The fractions were then concentrated in vacuo.
The H2O fractions were also concentrated in vacuo but showed no compounds of interest.
Hence, each screen resulted in six fractions: i) 30% Me2CO/H2O, ii) 75% Me2CO/H2O,
iii) 100% Me2CO fractions from the culture filtrate and iv) 30% Me2CO/H2O, v) 75%
Me2CO/H2O, vi) 100% Me2CO fractions from the cell mass extract.
5.3 Isolation of 1-acetyl-β-carboline from A. flavithermus
A 2 L liquid culture of A. flavithermus, obtained from GNS Science, was filtered using
celite and filter paper to separate the supernatant from any existing cell mass. The filtered
supernatant was then passed through a 50 mL HP20 column that had been washed with
Me2CO and MeOH and pre-equilibrated in H2O. The column was then eluted with 150
mL portions of i) H2O, ii) 30% Me2CO/H2O, iii) 75% Me2CO/H2O and iv) 100% Me2CO.
The 100% Me2CO fraction was concentrated in vacuo to give CDB01 61C (2.3 mg).
The 30% and 75% fractions were backloaded onto 30 mL and 15 mL HP20 columns,
respectively. The columns were then eluted with 90 mL and 45 mL 100% Me2CO,
respectively. The fractions were then concentrated in vacuo to give CDB01 61A (995.7
mg) and CDB01 61B (207 mg). The cell mass and celite were extracted overnight twice,
first in 80% MeOH and second in 100% MeOH. The second extract was passed through
a pre-equilibrated 50 mL HP20 column, followed by the first extract. The extracts were
then collected together and cyclic loaded onto the same column. The column was then
eluted with 150 mL portions of i) H2O, ii) 30% Me2CO/H2O, iii) 75% Me2CO/H2O
and iv) 100% Me2CO. The 100% Me2CO fraction was concentrated in vacuo to give
CDB01 62F (3.2 mg). The 30% and 75% fractions were backloaded onto 40 mL and
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20 mL HP20 columns, respectively. The columns were then eluted with 120 mL and 60
mL 100% Me2CO, respectively. The fractions were then concentrated in vacuo to give
CDB01 62D (9.5 mg) and CDB01 62E (5.9 mg).
CDB01 61B (207 mg) was cyclic loaded onto 10 mL HP20ss, which was then transferred
as a slurry onto a 40 mL pre-equilibrated HP20ss column. The column was eluted with
150 mL portions of 40%, 50%, 60%, 70%, 80%, 90% MeOH/H2O and finally 100%
MeOH. The 40%, 50% and 100% (CDB01 68E, 1.6 mg) fractions were collected in bulk
while the others were collected across 96 test tubes. The test tube fractions were analysed
by TLC and combined. NMR and MS analysis of CDB01 68E showed that it contained
impure 1-acetyl-β-carboline (1.6 mg).
1-acetyl-β-carboline (25). Pale yellow film, 1.6 mg; NMR data see Table 2.1;73
HRESIMS [M + H]+ m/z 211.0868 for C13H11N2O (calculated 211.0866, m/z ∆ =
0.0002).
5.4 Isolation of Compounds from Shewanella sp.
A 20 L liquid culture of Shewanella sp., obtained from Callaghan Innovation, was filtered
using celite and filter paper to separate the supernatant from any existing cell mass.
The filtered supernatant was then passed through a 50 mL HP20 column that had been
washed with Me2CO and MeOH and pre-equilibrated in H2O. The column was then
eluted with 150 mL portions of i) H2O, ii) 30% Me2CO/H2O, iii) 75% Me2CO/H2O
and iv) 100% Me2CO. The 100% Me2CO fraction was concentrated in vacuo to give
CDB01 57C (837.4 mg). The 30% and 75% fractions were backloaded onto 30 mL and
15 mL HP20 columns, respectively. The columns were then eluted with 90 mL and 45
mL 100% Me2CO, respectively. The fractions were then concentrated in vacuo to give
CDB01 57A (552.3 mg) and CDB01 57B (204.7 mg). The cell mass and celite were
extracted overnight twice, first in 80% MeOH and second in 100% MeOH. The second
extract was passed through a pre-equilibrated 100 mL HP20 column, followed by the first
extract. The extracts were then collected together and cyclic loaded onto the same column.
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The column was then eluted with 300 mL portions of i) H2O, ii) 30% Me2CO/H2O, iii)
75% Me2CO/H2O and iv) 100% Me2CO. The 100% Me2CO fraction was concentrated in
vacuo to give CDB01 62C (184.6 mg). The 30% and 75% fractions were backloaded onto
50 mL and 25 mL HP20 columns, respectively. The columns were then eluted with 150
mL and 75 mL 100% Me2CO, respectively. The fractions were then concentrated in vacuo
to give CDB01 62A (30.9 mg) and CDB01 62B (101.8 mg). A second 13 L liquid culture
of Shewanella sp. was obtained from Callaghan Innovation and was treated the same way
as described above to give fractions CDB01 83C (30%) (987.1 mg), CDB01 83D (75%)
(767 mg) and CDB01 83E (100%) (2.27 g). NMR analysis of the fractions from the
second culture showed that they were identical to the first culture.
5.4.1 Isolation of Indole-3-carboxaldehyde and Cyclo(L-Trp-L-Pro)
CDB01 57B (204.7 mg) was cyclic loaded onto 10 mL HP20ss, which was then
transferred as a slurry onto a 40 mL pre-equilibrated HP20ss column and eluted with
150 mL portions of 40%, 50%, 60%, 70%, 80%, 90% MeOH/H2O and finally 100%
MeOH. The 40%, 50% and 100% fractions were collected in bulk while the others were
collected across 88 test tubes. The test tube fractions were analysed by TLC and combined
to give ten fractions (CDB01 67A-J). 1H NMR analysis of CDB01 67B (2.7 mg) and
CDB01 67C (3.4 mg) revealed that they were similar. The two fractions were combined
and dissolved in 100% MeOH, and were then loaded onto a 100 g LH-20 column, which
had been pre-equilibrated in 100% MeOH. The column was eluted with ∼300 mL 100%
MeOH and collected across 114 tubes. The test tube fractions were analysed by TLC and
combined to give ten fractions (CDB01 73D-M). CDB01 73K (3.7 mg) was adsorbed
onto 0.1 mL of DIOL, which was then transferred as a slurry in hexane onto a 0.9 mL
DIOL column that had been pre-equilibrated in hexane. The column was eluted with 3
mL portions of i) 100% hexane, ii) 25% ethyl acetate (EA) in hexane, iii) 50% EA in
hexane (CDB01 77C, 1.1 mg), iv) 100% EA (CDB01 77D, 2 mg), v) 25% MeOH in
EA, vi) 50% MeOH in EA and vii) 100% MeOH. NMR and MS analysis revealed that
CDB01 77C contained indole-3-carboxaldehyde (1.1 mg).
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CDB01 77D (2 mg) was separated further using reversed-phase (C18) analytical HPLC
on the Rainin HPLC system, eluting with MeCN/H2O at a flow rate of 1 mL/min. The
method held the solvent mixture at 45% MeCN for eight minutes followed by a two
minute ramp to 100% MeCN, holding at 100% for five minutes, there was then a two
minute ramp back to 45% MeCN and finally the solvent mixture was held at 45% MeCN
for five minutes (22 minutes total), and fractions CDB01 80A (0.4 mg), B (0.1 mg), C
(tR = 3.5 min) containing pure cyclo(L-Trp-L-Pro) (0.5 mg), and D-N (0.7 mg) were
collected. The same protocol was followed for CDB01 83D (767 mg) and identical
fractions were combined together.
Indole-3-carboxaldehyde (93). Colourless film, 4.8 mg; NMR data see Table 3.4;165
HRESIMS [M + H]+ m/z 146.0597 for C9H8NO (calculated 146.0600, m/z ∆ = -0.0003).
Cyclo(L-Trp-L-Pro) (53). Pale yellow film, 1.9 mg; [α]25D = -70 (c = 0.1, MeOH);166
NMR data see Table 3.5;166 HRESIMS [M + H]+ m/z 284.1392 for C16H18N3O2
(calculated 284.1394, m/z ∆ = -0.0002); MS/MS fragments m/z 170.0571 for C11H8NO
(calculated 170.0600, m/z ∆ = -0.0029), m/z 130.0638 for C9H8N (calculated 130.0651,
m/z ∆ = -0.0013).167
5.4.2 Isolation of 2,5-DKPs from the 30% Fraction
The two 30% Me2CO/H2O fractions, CDB01 57A (552.3 mg) and CDB01 83C (987.1
mg), from both the culture filtrates were combined together. A 300 mg sub-sample of
the mixture was dissolved in 50% MeOH/H2O and loaded onto a 100 g LH-20 column,
which had been pre-equilibrated in 50% MeOH/H2O. The column was eluted with ∼300
mL 50% MeOH/H2O and collected across 88 tubes. The test tube fractions were analysed
by TLC and combined to give nine fractions (CDB02 26A-I). NMR analysis of these
fractions revealed that fractions CDB02 26C-G contained mixtures of 2,5-DKPs. The
remainder of the combined 30% fraction was subjected to LH-20 chromatography over
four more runs (∼300 mg per run), and using TLC analysis, fractions were combined
with those from the first LH-20 run. Fractions CDB02 26D-G were separated further by
reversed-phase (C18) HPLC as described below.
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CDB02 26C (419.5 mg) was cyclic loaded onto 17 mL HP20ss, which was then
transferred as a slurry onto a 53 mL pre-equilibrated HP20ss column and eluted with
210 mL portions of 10%, 20%, 30%, 40%, 50%, 80% MeOH/H2O and finally 100%
MeOH. The 10%, 20%, 80% (CDB02 33C, 70.7 mg) and 100% fractions were collected
in bulk while the others were collected across 110 test tubes. The test tube fractions were
analysed by TLC and combined to give six fractions (CDB02 33E-J).
Cyclo(L-Phe-L-4-Hyp)
A 50 mg sub-sample of HP20ss fraction CDB02 33I (134.7 mg) was dissolved in 20%
MeCN/H2O and purified using semi-preparative HPLC on the Agilent HPLC system,
eluting with MeCN/H2O (both with 0.1% formic acid) at a flow rate of 4 mL/min. The
method started with a ten mintue ramp from 15% MeCN to 20% MeCN, holding at 20%
for three minutes, there was then a one minute ramp back to 15% MeCN and finally the
solvent mixture was held at 15% MeCN for five minutes (19 minutes total), and fractions
CDB02 34A (7.5 mg) and B (tR = 11 min) were collected, the latter of which contained
pure cyclo(L-Phe-L-4-Hyp) (37.2 mg).
Cyclo(L-Phe-L-4-Hyp) (43). Viscous colourless film, 37.2 mg; [α]25D = -98 (c =
1.77, MeOH);168 NMR data see Table 3.6;106 HRESIMS [M + H]+ m/z 261.1237 for
C14H17N2O3 (calculated 261.1234, m/z ∆ = 0.0003); MS/MS fragments m/z 170.0695 for
C7H10N2O3 (calculated 170.0691, m/z ∆ = 0.0004), m/z 120.0798 for C8H10N (calculated
120.0808, m/z ∆ = -0.0010), m/z 114.0539 for C5H8NO2 (calculated 114.0550, m/z ∆ =
0.0011), m/z 103.0538 for C8H7 (calculated 103.0542, m/z ∆ = -0.0004).169
Cyclo(L-Leu-L-4-Hyp)
HP20ss fraction CDB02 33F (35.9 mg) was dissolved in 20% MeOH/H2O and purified
using semi-preparative HPLC (Agilent), eluting with MeOH/H2O (both with 0.1% formic
acid) at a flow rate of 4 mL/min. The method started with a five minute ramp from 20%
MeOH to 30% MeOH, holding at 30% for five minutes, there was then a two minute
ramp back to 20% MeOH and finally the solvent mixture was held at 20% MeOH for five
minutes (17 minutes total), and fractions CDB02 35A (2.3 mg) and B (tR = 12 min) were
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collected, the latter of which contained pure cyclo(L-Leu-L-4-Hyp) (25.3 mg).
Cyclo(L-Leu-L-4-Hyp) (42). Amorphous white solid, 25.3 mg; [α]25D = -123 (c =
1.15, MeOH);168 NMR data see Table 3.7;100 HRESIMS [M + H]+ m/z 227.1392 for
C11H19N2O3 (calculated 227.1390, m/z ∆ = 0.0002); MS/MS fragments m/z 199.1437
for C10H19N2O2 (calculated 199.1441, m/z ∆ = -0.0004), m/z 170.0678 for C7H10N2O3
(calculated 170.0686, m/z ∆ = -0.0008), m/z 136.1124 for C9H14N (calculated 136.1121,
m/z ∆ = 0.0003), m/z 114.0916 for C6H12NO (calculated 114.0913, m/z ∆ = 0.0003), m/z
86.0963 for C5H12N (calculated 86.0964, m/z ∆ = -0.0001), m/z 86.0608 for C4H8NO
(calculated 86.0600, m/z ∆ = 0.0008), m/z 68.0500 for C4H6N (calculated 68.0495, m/z
∆ = 0.0005).169
Cyclo(L-Leu-L-Pro)
HP20ss fraction CDB02 33J (52.6 mg) was dissolved in 50% MeOH/H2O and purified
using semi-preparative HPLC (Agilent), eluting with MeOH/H2O (both with 0.1% formic
acid) at a flow rate of 4 mL/min. The method started with a ten minute ramp from 40%
MeOH to 50% MeOH, holding at 50% for five minutes, there was then a one minute
ramp back to 40% MeOH and finally the solvent mixture was held at 40% MeOH for
five minutes (21 minutes total), and fractions CDB02 35G-H (10.4 mg), I (tR = 8.5 min)
containing pure cyclo(L-Leu-L-Pro) (21.9 mg), J (tR = 9.5 min, 2.4 mg), and K (5.3 mg)
were collected. CDB02 35J contained another impure 2,5-DKP that was purified later
(described below).
Cyclo(L-Leu-L-Pro) (44). Amorphous white solid, 21.9 mg; [α]25D = -127 (c = 0.89,
MeOH);172 NMR data as previously reported;100 HRESIMS [M + H]+ m/z 211.1445 for
C11H19N2O2 (calculated 211.1441, m/z ∆ = 0.0004); MS/MS fragments m/z 183.1498 for
C10H19N2O (calculated 183.1492, m/z ∆ = 0.0006), m/z 138.1273 for C9H16N (calculated
138.1277, m/z ∆ = -0.0004), m/z 114.0906 for C6H12NO (calculated 114.0913, m/z ∆ =
-0.0007), m/z 98.0599 for C5H8NO (calculated 98.0600, m/z ∆ = -0.0001), m/z 86.0974
for C5H12N (calculated 86.0964, m/z ∆ = 0.0010), m/z 70.0655 for C4H8N (calculated
70.0651, m/z ∆ = 0.0004).169
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Cyclo(L-Val-L-Pro) and Cyclo(Phe-4-Hyp)
HP20ss fraction CDB02 33H (27.5 mg) was dissolved in 20% MeOH/H2O and purified
using semi-preparative HPLC (Agilent), eluting with MeOH/H2O (both with 0.1% formic
acid) at a flow rate of 4 mL/min. The method started with a ten minute ramp from 20%
MeOH to 30% MeOH, holding at 30% for five minutes, there was then a one minute
ramp back to 20% MeOH and finally the solvent mixture was held at 20% MeOH for five
minutes (21 minutes total), and fractions CDB02 35C (1.7 mg), D (tR = 8 min) containing
pure cyclo(L-Val-L-Pro) (0.5 mg), E (tR = 10.5 min) containing impure cyclo(Phe-4-Hyp)
(5.4 mg), and F (12.2 mg) were collected.
Cyclo(L-Val-L-Pro) (41). Amorphous white solid, 0.5 mg; [α]25D = -150 (c = 0.04,
MeOH);101 NMR data as previously reported;100 HRESIMS [M + H]+ m/z 197.1290 for
C10H17N2O2 (calculated 197.1285, m/z ∆ = 0.0005); MS/MS fragments m/z 154.0746
for C7H10N2O2 (calculated 154.0737, m/z ∆ = 0.0009), m/z 100.0766 for C5H10NO
(calculated 100.0757, m/z ∆ = 0.0009), m/z 98.0608 for C5H8NO (calculated 98.0600,
m/z ∆ = 0.0008), m/z 72.0816 for C4H10N (calculated 72.0808, m/z ∆ = 0.0008), m/z
70.0662 for C4H8N (calculated 70.0651, m/z ∆ = 0.0011).173
Cyclo(Phe-4-Hyp) (94). Colourless film, 5.4 mg; NMR data as previously reported;107
HRESIMS [M + H]+ m/z 261.1237 for C14H17N2O3 (calculated 261.1234, m/z ∆ =
0.0003); MS/MS fragments m/z 233.1212 for C13H16N2O2 (calculated 233.1172, m/z ∆
= 0.0040), m/z 215.1104 for C13H14N2O (calculated 215.1067, m/z ∆ = 0.0037), m/z
170.0830 for C7H10N2O3 (calculated 170.0838, m/z ∆ = -0.0008), m/z 120.0807 for
C8H10N (calculated 120.0808, m/z ∆ = -0.0001), m/z 103.0543 for C8H7 (calculated
103.0542, m/z ∆ = 0.0001), m/z 91.0545 for C7H7 (calculated 91.0542, m/z ∆ = 0.0003),
m/z 86.0603 for C4H8NO (calculated 86.0600, m/z ∆ = 0.0003), m/z 68.0499 for C4H6N
(calculated 68.0495, m/z ∆ = 0.0004).169
Cyclo(Trp-Val), Cyclo(Trp-Ala) and Cyclo(L-Trp-D-Pro)
LH-20 fractions CDB02 26F (3.6 mg) and G (9 mg) were combined together, dissolved
in 20% MeCN/H2O, and subjected to semi-preparative HPLC (Agilent), eluting with
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MeCN/H2O (both with 0.1% formic acid) at a flow rate of 4 mL/min. The method started
with a 23 minute ramp from 20% MeCN to 27.7% MeCN, followed by a two minute
ramp back to 20% MeCN and finally the solvent mixture was held at 20% MeCN for
five minutes (30 minutes total), and fractions CDB02 28A-C (2.6 mg), D (tR = 6.5 min)
containing impure cyclo(Trp-Ala) (0.1 mg), E (0.6 mg), F (tR = 12.5 min) containing
impure cyclo(Trp-Pro) (0.8 mg), G-H, and I (tR = 16 min) containing impure cyclo(Trp-
Val) (0.3 mg) were collected.
LH-20 fraction CDB02 26E (3.5 mg) was dissolved in 20% MeCN/H2O and purified
using semi-preparative HPLC (Agilent), eluting with MeCN/H2O (both with 0.1% formic
acid) at a flow rate of 4 mL/min. The method held the solvent mixture at 20% MeCN
for five minutes followed by a twenty minute ramp to 28.3% MeCN, there was then a
two minute ramp back to 20% MeCN and finally the solvent mixture was held at 20%
MeCN for five minutes (32 minutes total), and fractions CDB02 29A-C (1.3 mg), D (tR
= 9.5 min) containing impure cyclo(Trp-Ala) (0.1 mg), E (0.1 mg) and F (tR = 13 min)
containing impure cyclo(Trp-Pro) (1.1 mg) were collected. Fractions CDB02 28D and
29D were combined together (into sample CDB02 28D) as they were identical.
HPLC fractions CDB02 28F (0.8 mg) and 29F (1.1 mg) were combined together,
dissolved in 20% MeCN/H2O, and subjected to semi-preparative HPLC (Agilent), eluting
with MeCN/H2O (both with 0.1% formic acid) at a flow rate of 4 mL/min. The method
started with a eight minute ramp from 20% MeCN to 25.3% MeCN, followed by a
one minute ramp back to 20% MeCN and finally the solvent mixture was held at 20%
MeCN for five minutes (14 minutes total), and one fraction, CDB02 31D (tR = 10.5 min)
containing pure cyclo(L-Trp-D-Pro) (0.8 mg) was collected.
Cyclo(Trp-Val) (99). Colourless film, 0.3 mg; NMR data as previously reported;177
HRESIMS [M + Na]+ m/z 308.1369 for C16H19N3O2Na (calculated 308.1369, m/z ∆
= 0.0000); MS/MS data see Table 3.10.
Cyclo(Trp-Ala) (98). Colourless film, 0.2 mg; NMR data as previously reported;176
HRESIMS [M + H]+ m/z 258.1242 for C14H16N3O2 (calculated 258.1237, m/z ∆ =
0.0005); MS/MS data see Table 3.9.
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Cyclo(L-Trp-D-Pro) (54). Colourless film, 0.8 mg; [α]25D = +94 (c = 0.05, MeOH);117
NMR data as previously reported;117 HRESIMS [M + H]+ m/z 284.1388 for C16H18N3O2
(calculated 284.1394, m/z ∆ = -0.0006); MS/MS fragments m/z 153.0636 for C7H9N2O2
(calculated 153.0659, m/z ∆ = -0.0023), m/z 130.0645 for C9H8N (calculated 130.0651,
m/z ∆ = -0.0006).167
Cyclo(L-Tyr-L-Pro) and Cyclo(Phe-Leu)
LH-20 fraction CDB02 26D (12.5 mg) was dissolved in 20% MeCN/H2O and purified
using semi-preparative HPLC (Agilent), eluting with MeCN/H2O (both with 0.1% formic
acid) at a flow rate of 4 mL/min. The method held the solvent mixture at 20% MeCN
for five minutes followed by a ten minute ramp to 24.2% MeCN, there was then a two
minute ramp back to 20% MeCN and finally the solvent mixture was held at 20% MeCN
for five minutes (22 minutes total), and fractions CDB02 30A-D (2.3 mg), E (tR = 5 min)
containing pure cyclo(L-Tyr-L-Pro) (3.8 mg), F (tR = 8 min) containing impure cyclo(Phe-
Leu) (0.2 mg), and G-L (4.9 mg) were collected.
Cyclo(L-Tyr-L-Pro) (38). Colourless film, 3.8 mg; [α]25D = -59 (c = 0.25, MeOH);174
NMR data as previously reported;175 HRESIMS [M + H]+ m/z 261.1233 for C14H17N2O3
(calculated 261.1234, m/z ∆ = -0.0001); MS/MS fragments m/z 154.0721 for C7H10N2O2
(calculated 154.0742, m/z ∆ = -0.0021), m/z 136.0747 for C8H10NO (calculated 136.0757,
m/z ∆ = -0.0010), m/z 119.0476 for C8H7O (calculated 119.0491, m/z ∆ = -0.0015), m/z
107.0489 for C7H7O (calculated 107.0491, m/z ∆ = -0.0002).173
Cyclo(Phe-Leu) (97). Colourless film, 0.2 mg; NMR data as previously reported;171
HRESIMS [M + H]+ m/z 261.1596 for C15H21N2O2 (calculated 261.1598, m/z ∆ = -
0.0002); MS/MS fragments m/z 170.1069 for C8H14N2O2 (calculated 170.1055, m/z ∆ =
0.0014), m/z 120.0808 for C8H10N (calculated 120.0808, m/z ∆ = 0.0000), m/z 114.0916
for C6H12NO (calculated 114.0913, m/z ∆ = 0.0003), m/z 105.0698 for C8H9 (calculated
105.0699, m/z ∆ = -0.0001), m/z 103.0543 for C8H7 (calculated 103.0542, m/z ∆ =
0.0001), m/z 91.0546 for C7H7 (calculated 91.0542, m/z ∆ = 0.0004), m/z 86.0967 for
C5H12N (calculated 86.0964, m/z ∆ = 0.0003).167
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Cyclo(L-Phe-D-Pro), Cyclo(Phe-6-Hyp) and Cyclo(Phe-Pro)
HP20ss fraction CDB02 33C (70.7 mg) was dissolved in 20% MeCN/H2O and purified
using semi-preparative HPLC (Agilent), eluting with MeCN/H2O (both with 0.1% formic
acid) at a flow rate of 4 mL/min. The method started with a ten minute ramp from 15%
MeCN to 20% MeCN, holding at 20% for five minutes, followed by a one minute ramp
back to 15% MeCN and finally the solvent mixture was held at 15% MeCN for five
minutes (21 minutes total), and fractions CDB02 34C (6.5 mg), D (tR = 14 min, 4.3 mg),
and E (tR = 16.5 min, 31.2 mg) were collected. Fraction CDB02 34D was identical to
CDB02 35J, and CDB02 34E contained a mixture of more 2,5-DKPs.
HPLC fractions CDB02 34D (4.3 mg) and 35J (2.4 mg) were combined together,
dissolved in 50% MeCN/H2O, and subjected to semi-preparative HPLC (Agilent), eluting
with MeCN/H2O (both with 0.1% formic acid) at a flow rate of 4 mL/min. The method
held the solvent mixture at 40% MeCN for ten minutes, and one fraction, CDB02 37A
(tR = 4.5 min) containing cyclo(L-Phe-D-Pro) (4.2 mg) was collected.
HPLC fraction CDB02 34E (31.2 mg) was dissolved in 20% MeCN/H2O, and subjected
to semi-preparative HPLC (Agilent), eluting with MeCN/H2O (both with 0.1% formic
acid) at a flow rate of 4 mL/min. The method started with a five minute ramp from 15%
MeCN to 20% MeCN, followed by another thirteen minute ramp to 20.8%, there was then
a two minute ramp back to 15% MeCN and finally the solvent mixture was held at 15%
MeCN for five minutes (25 minutes total), and fractions CDB02 36D-F (9.3 mg), G (tR
= 11 min) containing impure cyclo(Phe-6-Hyp) (5.3 mg), H (4.4 mg), I (tR = 14.5 min)
containing impure cyclo(Phe-Pro) (2.9 mg), and J (3.2 mg) were collected.
Cyclo(L-Phe-D-Pro) (36). Colourless film, 4.2 mg; [α]25D = +61 (c = 0.28, MeOH);
NMR data as previously reported;170 HRESIMS [M + H]+ m/z 245.1283 for C14H17N2O2
(calculated 245.1285, m/z ∆ = -0.0002); MS/MS fragments m/z 217.1319 for C13H16N2O
(calculated 217.1335, m/z ∆ = -0.0016), m/z 172.1115 for C12H14N (calculated 172.1121,
m/z ∆ = -0.0006), m/z 120.0804 for C8H10N (calculated 120.0808, m/z ∆ = -0.0004), m/z
103.0538 for C8H7 (calculated 103.0542, m/z ∆ = -0.0004), m/z 98.0595 for C5H8NO
(calculated 98.0600, m/z ∆ = -0.0005), m/z 70.0652 for C4H8N (calculated 70.0651, m/z
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∆ = 0.0001).169
Cyclo(Phe-6-Hyp) (95). Colourless film, 5.3 mg; NMR data as previously reported;104
HRESIMS [M + H]+ m/z 261.1241 for C14H17N2O3 (calculated 261.1234, m/z ∆ =
0.0007); MS/MS data see Table 3.8.
Cyclo(Phe-Pro) (96). Colourless film, 2.9 mg; NMR data as previously reported;106
HRESIMS [M + H]+ m/z 245.1289 for C14H17N2O2 (calculated 245.1285, m/z ∆ =
0.0004); MS/MS fragments m/z 217.1300 for C13H16N2O (calculated 217.1335, m/z ∆ = -
0.0035), m/z 172.1109 for C12H14N (calculated 172.1121, m/z ∆ = -0.0002), m/z 120.0806
for C8H10N (calculated 120.0808, m/z ∆ = -0.0002), m/z 103.0539 for C8H7 (calculated
103.0542, m/z ∆ = -0.0003), m/z 98.0599 for C5H8NO (calculated 98.0600, m/z ∆ = -
0.0001), m/z 91.0536 for C7H7 (calculated 91.0542, m/z ∆ = -0.0006), m/z 70.0655 for
C4H8N (calculated 70.0651, m/z ∆ = 0.0004).169
90
Appendix A
Microbial Culture Conditions
Table A.1. Aerobic culture conditions for the extremophilic microbes
Microbe Medium Temp. ( ◦C) pH
NGM11.1 R2AG 69 7.2
NGM22.9 R2AG 60 7.2
WAP10.3.2 R2AG 60 7.2
WC14 PDB 60 5.6
WK1 TSB 60 7.3
T49 4.5NZS10.2A 60 5.1
K22 R2AG 60 6.5
P373 R2AG 60 7.2
WKT50.2 10xCPS 69 7.5
Shewanella sp. PYM 15 -
A.1 Culture Media Components
All culture media were water-based.
R2AG Medium - 1 L
R2A - 9 g
MgCl2.6H2O - 1 g
Distilled H2O - 1 L
Potato Dextrose Broth (PDB) Medium - 1 L
Pre-prepared PDB media (Difco) - 24 g made up of:
Potato starch - 4 g
Dextrose - 20 g
Distilled H2O - 1 L
Tryptic Soy Broth (TSB) Medium - 1 L
Pre-prepared TSB media (Difco) - 30 g made up of:
Pancreatic digest of casein - 17 g
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Papaic digest of soybean - 3 g
Dextrose - 2.5 g
NaCl - 5 g
K2HPO4 - 2.5 g
Distilled H2O - 1 L
4.5NZS10.2A Medium - 1 L
NH4Cl - 4 g
KH2PO4 - 0.5 g
MgSO4 - 0.2 g
CaCl2 - 0.1 g
Yeast extract - 0.5 g
FeEDTA solution - 3 mL
Trace metal solution (Methanotrophs) - 3 mL
Methanogen trace metal solution (Wolin) - 1 mL
Starch - 6 g
Distilled H2O - 1 L
10xCPS Medium - 1 L
Salt solution:
Nitrilotriacetic acid - 0.1 g
MgSO4.7H2O - 0.1 g
CaCl2.2H2O - 0.06 g
NaCl - 0.008 g
NaNO3 - 0.689 g
KNO3 - 0.103 g
Na2HPO4.12H2O - 0.111 g
FeCL2 solution (see below) - 1 mL
Nitsch element solution (see below) - 1 mL
Peptone - 5 g
Sucrose - 2.5 g
Distilled H2O - 1 L
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Adjust pH to 8.2
FeCl2 solution:
FeCl2.4H2O - 0.44 g
Distilled H2O - 1 L
Nitsch element solution:
H2SO4 - 50 µl
MnCl22.4H2O - 0.28 g
ZnSO4.7H2O - 0.05 g
H3BO3 - 0.05 g
CuSO4.5H2O - 0.016 g
Na2MoO4.2H2O - 0.0030 g
CoCl2.6H2O - 0.0046 g
Distilled H2O - 100 mL
Peptone-Yeast extract-Malt extract (PYM) Medium - 1L
Bactopeptone - 10 g
Yeast extract - 2.5 g
Meat extract - 2 g
Instant Ocean R© - 15 g
Reverse Osmosis H2O - 1 L
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Appendix B
NMR Spectra of 1-Acetyl-β-carboline
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1H NMR spectrum of 1-acetyl-β-carboline (25) (600 MHz, DMSO−d6)
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13C NMR spectrum of 1-acetyl-β-carboline (25) (150 MHz, DMSO−d6)
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COSY spectrum of 1-acetyl-β-carboline (25) (600 MHz, DMSO−d6)
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Mutliplicity-edited HSQC spectrum of 1-acetyl-β-carboline (25) showing methylenes in
blue and methyls and methines in red (600 MHz, DMSO−d6)
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HMBC spectrum of 1-acetyl-β-carboline (25) (600 MHz, DMSO−d6)
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Appendix C
NMR Spectra of Indole-3-carboxaldehyde
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1H NMR spectrum of indole-3-carboxaldehyde (93) (600 MHz, CD3OD)
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13C NMR spectrum of indole-3-carboxaldehyde (93) (150 MHz, CD3OD)
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COSY spectrum of indole-3-carboxaldehyde (93) (600 MHz, CD3OD)
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Mutliplicity-edited HSQC spectrum of indole-3-carboxaldehyde (93) showing
methylenes in blue and methyls and methines in red (600 MHz, CD3OD)
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HMBC spectrum of indole-3-carboxaldehyde (93) (600 MHz, CD3OD)
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Appendix D
NMR Spectra of 2,5-DKPs
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1H NMR spectrum of cyclo(L-Trp-L-Pro) (53) (600 MHz, CD3OD)
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13C NMR spectrum of cyclo(L-Trp-L-Pro) (53) (150 MHz, CD3OD)
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Mutliplicity-edited HSQC spectrum of cyclo(L-Trp-L-Pro) (53) showing methylenes in
blue and methyls and methines in red (600 MHz, CD3OD)
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HMBC spectrum of cyclo(L-Trp-L-Pro) (53) (600 MHz, CD3OD)
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1H NMR spectrum of cyclo(L-Phe-L-4-Hyp) (43) (600 MHz, CD3OD)
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13C NMR spectrum of cyclo(L-Phe-L-4-Hyp) (43) (150 MHz, CD3OD)
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COSY spectrum of cyclo(L-Phe-L-4-Hyp) (43) (600 MHz, CD3OD)
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Mutliplicity-edited HSQC spectrum of cyclo(L-Phe-L-4-Hyp) (43) showing methylenes
in blue and methyls and methines in red (600 MHz, CD3OD)
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HMBC spectrum of cyclo(L-Phe-L-4-Hyp) (43) (600 MHz, CD3OD)
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1H NMR spectrum of cyclo(L-Leu-L-4-Hyp) (42) (600 MHz, CD3OD)
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13C NMR spectrum of cyclo(L-Leu-L-4-Hyp) (42) (150 MHz, CD3OD)
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COSY spectrum of cyclo(L-Leu-L-4-Hyp) (42) (600 MHz, CD3OD)
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Mutliplicity-edited HSQC spectrum of cyclo(L-Leu-L-4-Hyp) (42) showing methylenes
in blue and methyls and methines in red (600 MHz, CD3OD)
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HMBC spectrum of cyclo(L-Leu-L-4-Hyp) (42) (600 MHz, CD3OD)
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1H NMR spectrum of cyclo(Phe-4-Hyp) (L-D/D-L) (94) (600 MHz, CDCl3)
119














	





























	






2f



 
13C NMR spectrum of cyclo(Phe-4-Hyp) (L-D/D-L) (94) (150 MHz, CDCl3)
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1H NMR spectrum of cyclo(Phe-6-Hyp) (L-L/D-D) (95) (600 MHz, CDCl3)
121














	





























	






2f



 
13C NMR spectrum of cyclo(Phe-6-Hyp) (L-L/D-D) (95) (150 MHz, CDCl3)
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1H NMR spectrum of cyclo(Phe-Pro) (L-L/D-D) (96) (600 MHz, CD3OD)
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13C NMR spectrum of cyclo(Phe-Pro) (L-L/D-D) (96) (150 MHz, CD3OD)
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1H NMR spectrum of cyclo(L-Phe-D-Pro) (36) (600 MHz, CDCl3)
125














	





























	






2f



 
13C NMR spectrum of cyclo(L-Phe-D-Pro) (36) (150 MHz, CDCl3)
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1H NMR spectrum of cyclo(Phe-Leu) (L-L/D-D) (97) (600 MHz, CD3OD)
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13C NMR spectrum of cyclo(Phe-Leu) (L-L/D-D) (97) (150 MHz, CD3OD)
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1H NMR spectrum of cyclo(L-Leu-L-Pro) (44) (600 MHz, CD3OD)
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13C NMR spectrum of cyclo(L-Leu-L-Pro) (44) (150 MHz, CD3OD)
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1H NMR spectrum of cyclo(L-Val-L-Pro) (41) (600 MHz, CD3OD)
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13C NMR spectrum of cyclo(L-Val-L-Pro) (41) (150 MHz, CD3OD)
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1H NMR spectrum of cyclo(L-Tyr-L-Pro) (38) (600 MHz, CD3OD)
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13C NMR spectrum of cyclo(L-Tyr-L-Pro) (38) (150 MHz, CD3OD)
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1H NMR spectrum of cyclo(L-Trp-D-Pro) (54) (600 MHz, CD3OD)
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13C NMR spectrum of cyclo(L-Trp-D-Pro) (54) (150 MHz, CD3OD)
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1H NMR spectrum of cyclo(Trp-Ala) (L-L/D-D) (98) (600 MHz, DMSO−d6)
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13C NMR spectrum of cyclo(Trp-Ala) (L-L/D-D) (98) (150 MHz, DMSO−d6)
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1H NMR spectrum of cyclo(Trp-Val) (L-L/D-D) (99) (600 MHz, CD3OD)
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13C NMR spectrum of cyclo(Trp-Val) (L-L/D-D) (99) (150 MHz, CD3OD)
140
References
1. Ji, H.-F.; Li, X.-J.; Zhang, H.-Y. EMBO Reports 2009, 10, 194–200.
2. Rishton, G. M. American Journal of Cardiology 2008, 101, 43D–49D.
3. Beutler, J. A. Current Protocols in Pharmacology 2009, 46, 9.11.1–9.11.21.
4. Wright, G. D. Nature Reviews Microbiology 2007, 5, 175–186.
5. Mishra, B. B.; Tiwari, V. K. European Journal of Medicinal Chemistry 2011, 46,
4769–4807.
6. Harvey, A. L. Drug Discovery Today 2008, 13, 894–901.
7. Newman, D. J.; Cragg, G. M. Journal of Natural Products 2012, 75, 311–335.
8. Lam, K. S. Trends in Microbiology 2007, 15, 279–289.
9. Miyadoh, S. Actinomycetologica 1993, 7, 100–106.
10. Demain, A. L.; Sanchez, S. The Journal of Antibiotics 2009, 62, 5–16.
11. Tan, C.; Tasaka, H.; Yu, K.-P.; Murphy, M. L.; Karnofsky, D. A. Cancer 1967, 20,
333–353.
12. Singh, S.; Kate, B. N.; Banerjee, U. C. Critical Reviews in Biotechnology 2005, 25,
73–95.
13. Jaiswal, P.; Singh, P. K.; Prasanna, R. Canadian Journal of Microbiology 2008, 54,
701–717.
14. Gademann, K.; Portmann, C. Current Organic Chemistry 2008, 12, 326–341.
15. Larsen, L. K.; Moore, R. E.; Patterson, G. M. L. Journal of Natural Products 1994,
57, 419–421.
16. Boyd, M. R. et al. Antimicrobial Agents and Chemotherapy 1997, 41, 1521–1530.
17. Schwartz, R. E.; Hirsch, C. F.; Sesin, D. F.; Flor, J. E.; Chartrain, M.;
Fromtling, R. E.; Harris, G. H.; Salvatore, M. J.; Liesch, J. M.; Yudin, K. Journal of
Industrial Microbiology and Biotechnology 1990, 5, 113–123.
18. Harvey, A. Drug Discovery Today 2000, 5, 294–300.
19. Ringel, S. M.; Greenough, R. C.; Roemer, S.; Connor, D.; Gutt, A. L.; Blair, B.;
Kanter, G. The Journal of Antibiotics 1977, 30, 371–375.
20. Schneiker, S. et al. Nature Biotechnology 2007, 25, 1281–1289.
21. Cheng, K. L.; Bradley, T.; Budman, D. R. Biologics 2008, 2, 789–811.
22. Imhoff, J. F.; Labes, A.; Wiese, J. Biotechnology Advances 2011, 29, 468–482.
23. Joint, I.; Muhling, M.; Querellou, J. Microbial Biotechnology 2010, 3, 564–575.
24. Zhang, L.; An, R.; Wang, J.; Sun, N.; Zhang, S.; Hu, J.; Kuai, J. Current Opinion in
Microbiology 2005, 8, 276–281.
141
25. Romero, F.; Espliego, F.; Prez Baz, J.; Garca de Quesada, T.; Grvalos, D.; de la
Calle, F.; Fernndez-Puentes, J. L. The Journal of Antibiotics 1997, 50, 734–737.
26. Feling, R. H.; Buchanan, G. O.; Mincer, T. J.; Kauffman, C. A.; Jensen, P. R.;
Fenical, W. Angewandte Chemie International Edition 2003, 42, 355–357.
27. Solanki, R.; Khanna, M.; Lal, R. Indian Journal of Microbiology 2008, 48, 410–431.
28. Biswas, T.; Zolova, O. E.; Lomb, F.; de la Calle, F.; Salas, J. A.; Tsodikov, O. V.;
Garneau-Tsodikova, S. Journal of Molecular Biology 2010, 397, 495–507.
29. Gerwick, W.; Moore, B. Chemistry and Biology 2012, 19, 85–98.
30. Belarbi, E. H.; Contreras Gmez, A.; Chisti, Y.; Garcia Camacho, F.;
Molina Grima, E. Biotechnology Advances 2003, 21, 585–598.
31. Stierle, A. C.; Cardellina, J. H.; Singleton, F. L. Cellular and Molecular Life
Sciences 1988, 44, 1021.
32. Elyakov, G. B.; Kuznetsova, T.; Mikhailov, V. V.; Maltsev, I. I.; Voinov, V. G.;
Fedoreyev, S. A. Cellular and Molecular Life Sciences 1991, 47, 632–633.
33. Brock, T. D.; Freeze, H. Journal of Bacteriology 1969, 98, 289–297.
34. Brock, T. D.; Brock, K. M.; Belly, R. T.; Weiss, R. L. Archives of Microbiology
1972, 84, 54–68.
35. Wilson, Z. E.; Brimble, M. A. Natural Product Reports 2009, 26, 44–71.
36. Horikoshi, K.; Antranikian, G.; Bull, A.; Robb, F.; Stetter, K. Extremophiles
Handbook; Springer, 2011.
37. Fujiwara, S. Journal of Bioscience and Bioengineering 2002, 94, 518–525.
38. Rothschild, L. J.; Mancinelli, R. L. Nature 2001, 409, 1092–1101.
39. Stierle, A. A.; Stierle, D. B.; Goldstein, E.; Parker, K.; Bugni, T.; Baarson, C.;
Gress, J.; Blake, D. Journal of Natural Products 2003, 66, 1097–1100.
40. Stierle, D. B.; Stierle, A. A.; Hobbs, J. D.; Stokken, J.; Clardy, J. Organic Letters
2004, 6, 1049–1052.
41. Stierle, A. A.; Stierle, D. B.; Kelly, K. The Journal of Organic Chemistry 2006, 71,
5357–5360.
42. Stierle, D. B.; Stierle, A. A.; Patacini, B. Journal of Natural Products 2007, 70,
1820–1823.
43. Stierle, A. A.; Stierle, D. B.; Patacini, B. Journal of Natural Products 2008, 71,
856–860.
44. Sarker, S. D.; Latif, Z.; Gray, A. I. Natural Products Isolation; Humana Press, 2005;
Vol. 20.
45. Houghton, P. J. Phytotherapy Research 2000, 14, 419–423.
46. Rahman, A.-u.; Choudhary, M. I.; Thomsen, W. J. Bioassay Techniques for Drug
Development; Harwood Academic Publishers, 2001.
142
47. Guza, R. C. Isolation of Natural Products from Casearia nigrescens, MSc Thesis,
2004.
48. Bohlin, L.; Bruhn, J. G. Bioassay Methods in Natural Product Research and Drug
Development; Springer Netherlands, 1999; Vol. 43.
49. MarinLit, Department of Chemistry, University of Canterbury,
http://www.chem.canterbury.ac.nz/marinlit/marinlit.shtml, 2013.
50. Laatsch, H. Antibase, A Database for Rapid Dereplication and Structure
Determination of Microbial Natural Products, Wiley-VCH:Weinheim, Germany,
2013.
51. Scifinder, American Chemical Society, http://www.cas.org/products/scifinder, 2014.
52. Keyzers, R. A. The Isolation of Biologically Active Secondary Metabolites from New
Zealand Marine Organisms, PhD Thesis, 2003.
53. Singh, A. J. The Structure-Directed Isolation of New Secondary Metabolites from
South Pacific Marine Sponges, PhD Thesis, 2012.
54. Barber, J. M. E. K. Chemical and Biological Aspects of Secondary Metabolites from
Tongan Marine Sponges, PhD Thesis, 2012.
55. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Advanced Drug
Delivery Reviews 1997, 23, 3–25.
56. West, L. M. The Isolation of Secondary Metabolites from New Zealand Marine
Sponges, PhD Thesis, 2001.
57. Hudson, J. A.; Morgan, H. W.; Daniel, R. M. International Journal of Systematic
Bacteriology 1987, 37, 431–436.
58. Fomenkov, A.; Xu, S. Gene 1995, 163, 109–113.
59. Choi, J. J.; Jung, S. E.; Kim, H.; Kwon, S. Biotechnology and Applied Biochemistry
1999, 30, 19–25.
60. Egas, M. C. V.; da Costa, M. S.; Cowan, D. A.; Pires, E. M. V. Extremophiles 1998,
2, 23–32.
61. Donk, P. J. Journal of Bacteriology 1920, 5, 373–374.
62. Watanabe, T.; Furukawa, S.; Hirata, J.; Koyama, T.; Ogihara, H.; Yamasaki, M.
Applied and Environmental Microbiology 2003, 69, 7124–7129.
63. Poli, A.; Esposito, E.; Lama, L.; Orlando, P.; Nicolaus, G.; de Appolonia, F.;
Gambacorta, A.; Nicolaus, B. Systematic and Applied Microbiology 2006, 29, 300–
307.
64. Poli, A.; Salerno, A.; Laezza, G.; di Donato, P.; Dumontet, S.; Nicolaus, B. Research
in Microbiology 2009, 160, 99–106.
65. Singh, S.; Madlala, A. M.; Prior, B. A. FEMS Microbiology Reviews 2003, 27, 3–16.
66. Mishra, R. S.; Maheshwari, R. Journal of Bioscience 1996, 21, 653672.
143
67. Puchart, V.; Katapodis, P.; Biely, P.; Kremnicky, L.; Christakopoulos, P.;
Vrsanska, M.; Kekos, D.; Macris, B. J.; Bhat, M. K. Enzyme and Microbial
Technology 1999, 24, 355–361.
68. Fernandez-Lafuente, R. Journal of Molecular Catalysis B: Enzymatic 2010, 62,
197–212.
69. Pikuta, E.; Lysenko, A.; Chuvilskaya, N.; Mendrock, U.; Hippe, H.; Suzina, N.;
Nikitin, D.; Osipov, G.; Laurinavichius, K. International Journal of Systematic and
Evolutionary Microbiology 2000, 6, 2109–2117.
70. Saw, J. H. et al. Genome Biology 2008, 9, 17–33.
71. Ellis, J. T.; Magnuson, T. S. ISRN Microbiology 2012, 517–524.
72. Liu, J.; Lei, Y.; Wang, F.; Yi, Y.; Liu, Y.; Wang, G. Journal of Applied Microbiology
2011, 5, 1365–2672.
73. Proksa, B.; Uhrn, D.; Surdkova, M.; Fuska, J. Acta Biotechnologica 1990, 10, 337–
340.
74. Bratchkova, A.; Ivanova, V.; Gousterova, A.; Laatsch, H. Biotechnology and
Biotechnological Equipment 2010, 26, 3005–3009.
75. Dillman, R. L.; Cardellina, J. H. Journal of Natural Products 1991, 54, 1056–1061.
76. Shaaban, M.; Schroder, D.; Shaaban, K. A.; Helmke, E.; Grun-Wollny, I.; Wagner-
Dobler, I.; Laatsch, H. Revista Latinoamericana de Qumica 2007, 35, 58–67.
77. Elleuch, L.; Shaaban, M.; Smaoui, S.; Mellouli, L.; Karray-Rebai, I.; Fourati-
Ben Fguira, L.; Shaaban, K. A.; Laatsch, H. Applied Biochemistry and
Biotechnology 2010, 162, 579–593.
78. Huang, H.; Yao, Y.; He, Z.; Yang, T.; Ma, J.; Tian, X.; Li, Y.; Huang, C.; Chen, X.;
Li, W.; Zhang, S.; Zhang, C.; Ju, J. Journal of Natural Products 2011, 74, 2122–
2127.
79. Shin, H. J.; Lee, H. S.; Lee, D. S. Journal of Microbiology and Biotechnology 2010,
20, 501–505.
80. Herraiz, T.; Chaparro, C. Biochemical and Biophysical Research Communications
2005, 326, 378–386.
81. Lee, K. C.; Dunfield, P. F.; Morgan, X. C.; Crowe, M. A.; Houghton, K. M.;
Vyssotski, M.; Ryan, J. L. J.; Lagutin, K.; McDonald, I. R.; Stott, M. B.
International Journal of Systematic and Evolutionary Microbiology 2011, 61, 2482–
2490.
82. Vyssotski, M.; Lee, K. C.; Lagutin, K.; Ryan, J.; Morgan, X. C.; Stott, M. B. Lipids
2011, 46, 1155–1161.
83. Crowe, M.; Power, J. F.; Morgan, X. C.; Dunfield, P. F.; Lagutin, K.; Rijpstra, W. I.;
Rijpstra, I. C.; Sinninghe Damste, J. S.; Houghton, K. M.; Ryan, J. L.; Stott, M. B.
International Journal of Systematic and Evolutionary Microbiology 2014, 64, 220–
227.
144
84. Ferrer, M.; Golyshina, O.; Beloqui, A.; Golyshin, P. N. Current Opinion in
Microbiology 2007, 10, 207–14.
85. Borthwick, A. D. Chemical Reviews 2012, 112, 3641–3716.
86. Martins, M. B.; Carvalho, I. Tetrahedron 2007, 63, 9923–9932.
87. Dinsmore, C. J.; Beshore, D. C. Tetrahedron 2002, 58, 3297–3312.
88. Cava, F.; de Pedro, M. A.; Lam, H.; Davis, B. M.; Waldor, M. K. The EMBO Journal
2011, 30, 3442–3453.
89. Gondry, M. et al. Nature Chemical Biology 2009, 5, 414–420.
90. Gu, B.; He, S.; Yan, X.; Zhang, L. Applied Microbiology and Biotechnology 2013,
97, 8439–8453.
91. Belin, P.; Moutiez, M.; Lautru, S.; Seguin, J.; Pernodet, J.-L.; Gondry, M. Natural
Product Reports 2012, 29, 961–979.
92. Schultz, A. W.; Oh, D.-C.; Carney, J. R.; Williamson, R. T.; Udwary, D. W.;
Jensen, P. R.; Gould, S. J.; Fenical, W.; Moore, B. S. Journal of the American
Chemical Society 2008, 130, 4507–4516.
93. Lautru, S.; Gondry, M.; Genet, R.; Pernodet, J.-L. Chemistry and Biology 2002, 9,
1355–1364.
94. Tang, M. R.; Sternberg, D.; Behr, R. K.; Sloma, A.; Berka, R. M. Industrial
Biotechnology 2006, 2, 66–74.
95. Giessen, T. W.; von Tesmar, A. M.; Marahiel, M. A. Biochemistry 2013, 52, 4274–
4283.
96. Huang, R.; Zhou, X.; Xu, T.; Yang, X.; Liu, Y. Chemistry and Biodiversity 2010, 7,
2809–2829.
97. Cornacchia, C.; Cacciatore, I.; Baldassarre, L.; Mollica, A.; Feliciani, F.; Pinnen, F.
Mini Reviews in Medicinal Chemistry 2012, 12, 2–12.
98. Kumar, N.; Mohandas, C.; Nambisan, B.; Soban Kumar, D. R.; Lankalapalli, R. S.
World Journal of Microbiology and Biotechnology 2013, 29, 355–364.
99. Cain, C. C.; Lee, D.; Waldo, R. H.; Henry, A. T.; Casida, E. J.; Wani, M. C.;
Wall, M. E.; Oberlies, N. H.; Falkinham, J. O. Antimicrobial Agents and
Chemotherapy 2003, 47, 2113–2117.
100. Furtado, N. A. J. C.; Pupo, M. T.; Carvalho, I.; Campo, V. L.; Duarte, M. C. T.;
Bastos, J. K. Journal of the Brazilian Chemical Society 2005, 16, 1448–1453.
101. Mehnaz, S.; Saleem, R. S. Z.; Yameen, B.; Pianet, I.; Schnakenburg, G.;
Pietraszkiewicz, H.; Valeriote, F.; Josten, M.; Sahl, H.-G.; Franzblau, S. G.;
Gross, H. Journal of Natural Products 2013, 76, 135–141.
102. Cheenpracha, S.; Borris, R. P.; Tran, T. T.; Jee, J. M.; Seow, H. F.; Cheah, H.-Y.;
Ho, C. C.; Chang, L. C. Journal of the Brazilian Chemical Society 2011, 22, 223–
229.
145
103. Li, H.; Lee, B. C.; Kim, T. S.; Bae, K. S.; Hong, J.; Choi, S. H.; Bao, B.; Jung, J. H.
Biomolecules and Therapeutics 2008, 16, 356–363.
104. Park, Y. C.; Gunasekera, S. P.; Lopez, J. V.; McCarthy, P. J.; Wright, A. E. Journal
of Natural Products 2006, 69, 580–584.
105. Qi, S.-H.; Xu, Y.; Gao, J.; Qian, P.-Y.; Zhang, S. Annals of Microbiology 2009, 59,
229–233.
106. Strom, K.; Sjogren, J.; Broberg, A.; Schnrer, J. Applied and Environmental
Microbiology 2002, 68, 4322–4327.
107. Shigemori, H.; Tenma, M.; Shimazaki, K.; Kobayashi, J. Journal of Natural
Products 1998, 61, 696–698.
108. Li, X.-J.; Zhang, Q.; Zhang, A.-L.; Gao, J.-M. Journal of Agricultural and Food
Chemistry 2012, 60, 3424–3431.
109. Rhee, K.-H. Journal of Microbiology and Biotechnology 2003, 13, 984–988.
110. Rhee, K.-H.; Choi, K.-H.; Kim, C.-J.; Kim, C.-H. Journal of Microbiology and
Biotechnology 2001, 11, 469–474.
111. Rhee, K.-H. Journal of General and Applied Microbiology 2002, 48, 321–327.
112. Rhee, K.-H. International Journal of Antimicrobial Agents 2004, 24, 423–427.
113. Fdhila, F.; Vazquez, V.; Snchez, J. L.; Riguera, R. Journal of Natural Products 2003,
66, 1299–1301.
114. Birch, A. J.; Wright, J. J. Tetrahedron 1970, 26, 2329–44.
115. Li, X.; Dobretsov, S.; Xu, Y.; Xiao, X.; Hung, O. S.; Qian, P.-Y. Biofouling 2006,
22, 187–194.
116. Mehdi, R. B. A.; Shaaban, K. A.; Rebai, I. K.; Smaoui, S.; Bejar, S.; Mellouli, L.
Natural Product Research 2009, 23, 1095–1107.
117. Ying, Y.-M.; Shan, W.-G.; Liu, W.-H.; Zhan, Z.-J. Chemistry of Natural Compounds
2013, 49, 184–186.
118. Meng, X.; Tian, L.; Lin, W.; Li, Q. Chinese Journal of Marine Drugs 2009, 28,
6–10.
119. Sun, K.; Wang, Y.; Fu, P.; Liu, P.; Zhu, W. Chinese Journal of Marine Drugs 2013,
32, 37–45.
120. Brauns, S. C.; Milne, P.; Naud, R.; Venter, M. V. D. Anticancer Research 2004, 24,
1713–1720.
121. Brauns, S. C.; Dealtry, G.; Milne, P.; Naud, R.; Venter, M. V. D. Anticancer Research
2005, 25, 4197–4202.
122. Yamazaki, M.; Suzuki, S.; Miyaki, K. Chemical and Pharmaceutical Bulletin 1971,
19, 1739–1740.
146
123. Cole, R. J.; Kirksey, J. W.; Dorner, J. W.; Wilson, D. M.; Johnson Jr., J. C.;
Johnson, A. N.; Bedell, D. M.; Springer, J. P.; Chexal, K. K.; Clardy, J. C.;
Cox, R. H. Journal of Agricultural and Food Chemistry 1977, 25, 826–830.
124. Cole, R. J.; Kirksey, J. W.; Moore, J. H.; Blankenship, B. R.; Diener, U. L.;
Davis, N. D. Applied and Environmental Microbiology 1972, 24, 248–256.
125. Abraham, W.-R.; Arfmann, H.-A. Phytochemistry 1990, 29, 1025–1026.
126. Cui, C.-B.; Kakeya, H.; Okada, G.; Onose, R.; Osada, H. The Journal of Antibiotics
1996, 49, 527–533.
127. Usui, T.; Kondoh, M.; Cui, C.-B.; Mayumi, T.; Sada, H. Biochemical Journal 1998,
333, 543–548.
128. Woehlecke, H.; Osada, H.; Herrmann, A.; Lage, H. International Journal of Cancer
2003, 107, 721–728.
129. Rabindran, S. K.; Ross, D. D.; Doyle, L. A.; Yang, W.; Greenberger, L. M. Cancer
Research 2000, 60, 47–50.
130. Cui, C.-B.; Kakeya, H.; Osada, H. Tetrahedron 1996, 52, 12651–12666.
131. Cui, C.-B.; Kakeya, H.; Osada, H. Tetrahedron 1997, 53, 59–72.
132. Fazuo Wang, Y. F.; Zhu, T.; Zhang, M.; Lin, A.; Gu, Q.; Zhu, W. Tetrahedron 2008,
64, 7986–7991.
133. Afiyatullov, S. S.; Zhuravleva, O. I.; Chaikina, E. L.; Anisimov, M. M. Chemistry of
Natural Compounds 2012, 48, 95–98.
134. Garg, N.; Manchanda, G.; Kumar, A. Antonie van Leeuwenhoek 2014, 105, 289–
305.
135. Nazzaro, F.; Fratianni, F.; Coppola, R. International Journal of Molecular Sciences
2013, 14, 12607–12619.
136. Nealson, K. H.; Platt, T.; Hastings, J. W. Journal of Bacteriology 1970, 104, 313–
322.
137. Holden, M. T. G. et al. Molecular Microbiology 1999, 33, 1254–1266.
138. Yan, P.-S.; Song, Y.; Sakuno, E.; Nakajima, H.; Nakagawa, H.; Yabe, K. Applied
and Environmental Microbiology 2004, 70, 7466–7473.
139. Park, D.-K.; Lee, K.-E.; Baek, C.-H.; Kim, I. H.; Kwon, J.-H.; Lee, W. K.; Lee, K.-
H.; Kim, B.-S.; Choi, S.-H.; Kim, K.-S. Journal of Bacteriology 2006, 188, 2214–
2221.
140. Campbell, J.; Lin, Q.; Geske, G. D.; Blackwell, H. E. ACS Chemical Biology 2009,
4, 1051–1059.
141. Musthafa, K. S.; Balamurugan, K.; Pandian, S. K.; Ravi, A. V. Journal of Basic
Microbiology 2012, 52, 679–686.
142. Abed, R. M. M.; Dobretsov, S.; Al-Fori, M.; Gunasekera, S. P.; Sudesh, K.;
Paul, V. J. Journal of Industrial Microbiology and Biotechnology 2013, 40, 759–
772.
147
143. Holt, H. M.; Gahrn-Hansen, B.; Bruun, B. Clinical Microbiology and Infection
2005, 11, 347–352.
144. Hau, H. H.; Gralnick, J. A. Annual Review of Microbiology 2007, 61, 237–258.
145. Dikow, R. B. BMC Genomics 2011, 12, 237–250.
146. Chen, Y.; Liu, Y.; Yen, M.; Wang, J.; Wang, J.; Wann, S.; Cheng, D. Clinical
Infectious Diseases 1997, 25, 225–229.
147. Fredrickson, J. K. et al. Nature Reviews Microbiology 2008, 6, 592–603.
148. Derby, H.; Hammer, B. Iowa Agricultural Experiment Station Research Bulletin
1931, 145, 387–416.
149. MacDonell, M.; Colwell, R. Systematic and Applied Microbiology 1985, 6, 171–
182.
150. Murakawa, T.; Yamagata, H.; Tsuruta, H.; Aizono, Y. Bioscience, Biotechnology,
and Biochemistry 2002, 66, 754–761.
151. Malasarn, D.; Keeffe, J. R.; Newman, D. K. Journal of Bacteriology 2008, 190,
135–142.
152. Simoes, I.; Faro, R.; Bur, D.; Kay, J.; Faro, C. FEBS Journal 2011, 278, 3177–3186.
153. Kasahara, R.; Sato, T.; Tamegai, H.; Kato, C. Bioscience, Biotechnology, and
Biochemistry 2009, 73, 2541–2543.
154. Morita, J.; Suzuki, S. Journal of Marine Biotechnology 1994, 1, 197–202.
155. Godeke, J.; Heun, M.; Bubendorfer, S.; Paul, K.; Thormann, K. M. Applied and
Environmental Microbiology 2011, 77, 5342–5351.
156. Bodor, A.; Elxnat, B.; Thiel, V.; Schulz, S.; Wagner-Dobler, I. BMC Microbiology
2008, 8, 13–21.
157. Simidu, U.; Kita-Tsukamoto, K.; Yasumoto, T.; Yotsu, M. International Journal of
Systematic Bacteriology 1990, 40, 331–336.
158. Green, T. J.; Smullen, R.; Barnes, A. C. Veterinary Microbiology 2013, 166, 286–
292.
159. Defoirdt, T.; Boon, N.; Bossier, P.; Verstraete, W. Aquaculture 2004, 240, 69–88.
160. Bhattarai, H. D.; Ganti, V. S.; Paudel, B.; Lee, Y. K.; Lee, H. K.; Hong, Y.;
Shin, H. W. World Journal of Microbiology and Biotechnology 2007, 23, 243–249.
161. Nishida, T.; Morita, N.; Yano, Y.; Orikasa, Y.; Okuyama, H. FEBS Letters 2007,
581, 4212–4216.
162. Ledyard, K. M.; Butler, A. Journal of Biological Inorganic Chemistry 1997, 2, 93–
97.
163. Bottcher, T.; Clardy, J. Angewandte Chemie International Edition 2014, 53, 3510–
3513.
148
164. Gu, Q.; Fu, L.; Wang, Y.; Lin, J. Journal of Agricultural and Food Chemistry 2013,
61, 11645–11652.
165. Evident, A.; Surico, G. Journal of Natural Products 1986, 49, 938–939.
166. He, R.; Wang, B.; Wakimoto, T.; Wang, M.; Zhub, L.; Abe, I. Journal of the
Brazilian Chemical Society 2013, 24, 1926–1932.
167. Chen, Y.-H.; Liou, S.-E.; Chen, C.-C. European Food Research and Technology
2004, 218, 589–597.
168. Liu, H.; Chen, J.; Deng, Z.; Huang, H.-R.; Lin, W.-H. Journal of Chinese
Pharmaceutical Sciences 2010, 19, 482–486.
169. Furtado, N. A. J. C.; Vessecchi, R.; Tomaz, J. C.; Galembeck, S. E.; Bastos, J. K.;
Lopes, N. P.; Crotti, A. E. M. Journal of Mass Spectrometry 2007, 42, 1279–1286.
170. Wang, G.; Dai, S.; Chen, M.; Wu, H.; Xie, L.; Luo, X.; Li, X. Chemistry of Natural
Compounds 2010, 46, 583–585.
171. Takaya, Y.; Furukawa, T.; Miura, S.; Akutagawa, T.; Hotta, Y.; Ishikawa, N.;
Niwa, M. Journal of Agricultural and Food Chemistry 2006, 55, 75–79.
172. Jayatilake, G. S.; Thornton, M. P.; Leonard, A. C.; Grimwade, J. E.; Baker, B. J.
Journal of Natural Products 1996, 59, 293–296.
173. Stark, T.; Hofmann, T. Journal of Agricultural and Food Chemistry 2005, 53, 7222–
7231.
174. Lee, Y.-H. Studies on the bioactive constituents of the fermented broth of three
marine bacterial species isolated in Taiwan, Masters Thesis, 2008.
175. Smaoui, S.; Mathieu, F.; Elleuch, L.; Coppel, Y.; Merlina, G.; Karray-Rebai, I.;
Mellouli, L. World Journal of Microbiology and Biotechnology 2012, 28, 793–804.
176. Caballero, E.; Avendao, C.; Menndez, J. C. Tetrahedron: Asymmetry 1998, 9, 967–
981.
177. Pedras, M. S. C.; Smith, K. C.; Taylor, J. L. Phytochemistry 1998, 49, 1575–1577.
178. Izumida, H.; Imamura, N.; Sano, H. Journal of Antibiotics 1996, 49, 76–80.
179. Houston, D. R.; Eggleston, I.; Synstad, B.; Eijsink, V. G.; van Aalten, D. M. The
Biochemical Journal 2002, 368, 23–27.
180. Izumida, H.; Nishijima, M.; Takadera, T.; Nomoto, A. M.; Sano, H. Journal of
Antibiotics 1996, 49, 829–831.
181. Houston, D. R.; Synstad, B.; Eijsink, V. G. H.; Stark, M. J. R.; Eggleston, I. M.; van
Aalten, D. M. F. Journal of Medicinal Chemistry 2004, 47, 5713–5720.
149
